[{"role": "model", "parts": [{"text": "I am a large language model trained to be informative and comprehensive. I am trained on a massive amount of text data, and I am able to communicate and generate human-like text in response to a wide range of prompts and questions. For this task, I will act as a specialized assistant that can identify datasets mentioned in a publication and create a summary suitable for non-specialists.\n\nThe output should be a JSON array of objects, where each object has the following keys:\n- \"dataset_identifier\": This is any alphanumeric string (maybe including punctuation marks) that uniquely identifies or provides access to a dataset.\n- \"repository_reference\": This is the URL or reference to the data repository where the dataset can be found.\n\nHere are some examples for reference:\n\n['dataset_identifier'=> 'EGAS00001000925', 'repository_reference'=> 'https=>//ega-archive.org/datasets/EGAS00001000925',\n 'dataset_identifier'=> 'GSE69091', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69091',\n 'dataset_identifier'=> 'PRJNA306801', 'repository_reference'=> 'https=>//www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA306801',\n 'dataset_identifier'=> 'phs003416.v1.p1', 'repository_reference'=> 'dbGaP',\n 'dataset_identifier'=> 'PXD049309', 'repository_reference'=> 'https=>//www.ebi.ac.uk/pride/archive/projects/PXD049309',\n 'dataset_identifier'=> 'IPX0004230000', 'repository_reference'=> 'http=>//www.iprox.org',\n 'dataset_identifier'=> 'MSV000092944', 'repository_reference'=> 'https=>//massive.ucsd.edu/',\n 'dataset_identifier'=> 'n/a', 'repository_reference'=> 'https://data.broadinstitute.org/ccle_legacy_data/mRNA_expression/'\n]"}]}, {"role": "user", "parts": [{"text": "I have a webpage in HTML format (<html class=\"\" lang=\"en\"> <head> <link href=\"/static/assets/style-b3a36f11.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-ef962842.css\" rel=\"stylesheet\"/> <link href=\"/static/assets/style-3ade8b5c.css\" rel=\"stylesheet\"/> <link href=\"/static/img/favicons/apple-touch-icon.png\" rel=\"apple-touch-icon\" sizes=\"180x180\"/> <link href=\"/static/img/favicons/favicon-48x48.png\" rel=\"icon\" sizes=\"48x48\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-32x32.png\" rel=\"icon\" sizes=\"32x32\" type=\"image/png\"/> <link href=\"/static/img/favicons/favicon-16x16.png\" rel=\"icon\" sizes=\"16x16\" type=\"image/png\"/> <link href=\"/static/img/favicons/site.webmanifest\" rel=\"manifest\"/> <link color=\"#0071bc\" href=\"/static/img/favicons/safari-pinned-tab.svg\" rel=\"mask-icon\"/> <title> Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer - PMC </title> <link href=\"https://www.google-analytics.com\" rel=\"preconnect\"/> <link href=\"https://cdn.ncbi.nlm.nih.gov\" rel=\"preconnect\"/> <link href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11423856/\" rel=\"canonical\"/> </head> <body> <a class=\"usa-skipnav\" href=\"#main-content\"> Skip to main content </a> <section aria-label=\"Official website of the United States government\" class=\"usa-banner\"> <div class=\"usa-accordion\"> <header class=\"usa-banner__header\"> <div class=\"usa-banner__inner\"> <div class=\"grid-col-auto\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__header-flag\" src=\"/static/img/us_flag.svg\"/> </div> <div aria-hidden=\"true\" class=\"grid-col-fill tablet:grid-col-auto\"> <p class=\"usa-banner__header-text\"> An official website of the United States government </p> <span class=\"usa-banner__header-action\"> Here's how you know </span> </div> <button aria-controls=\"gov-banner-default\" aria-expanded=\"false\" class=\"usa-accordion__button usa-banner__button\" type=\"button\"> <span class=\"usa-banner__button-text\"> Here's how you know </span> </button> </div> </header> <div class=\"usa-banner__content usa-accordion__content\" hidden=\"\" id=\"gov-banner-default\"> <div class=\"grid-row grid-gap-lg\"> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-dot-gov.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Official websites use .gov </strong> <br/> A <strong> .gov </strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class=\"usa-banner__guidance tablet:grid-col-6\"> <img alt=\"\" aria-hidden=\"true\" class=\"usa-banner__icon usa-media-block__img\" src=\"/static/img/icon-https.svg\"/> <div class=\"usa-media-block__body\"> <p> <strong> Secure .gov websites use HTTPS </strong> <br/> A <strong> lock </strong> ( <span class=\"icon-lock\"> <svg aria-labelledby=\"banner-lock-description\" class=\"usa-banner__lock-image\" focusable=\"false\" height=\"64\" role=\"graphics-symbol\" viewbox=\"0 0 52 64\" width=\"52\" xmlns=\"http://www.w3.org/2000/svg\"> <title id=\"banner-lock-title\"> Lock </title> <desc id=\"banner-lock-description\"> Locked padlock icon </desc> <path d=\"M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z\" fill=\"#000000\" fill-rule=\"evenodd\"> </path> </svg> </span> ) or <strong> https:// </strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class=\"usa-overlay\"> </div> <header class=\"usa-header usa-header--extended usa-header--wide\"> <div class=\"ncbi-header\"> <div class=\"ncbi-header__container\"> <a class=\"ncbi-header__logo-container\" href=\"https://www.ncbi.nlm.nih.gov/\"> <img alt=\" NCBI home page \" class=\"ncbi-header__logo-image\" src=\"/static/img/ncbi-logos/nih-nlm-ncbi--white.svg\"/> </a> <button aria-label=\"Show menu\" class=\"usa-menu-btn ncbi-header__hamburger-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"ncbi-hamburger-icon\" fill=\"none\" focusable=\"false\" height=\"21\" viewbox=\"0 0 31 21\" width=\"31\" xmlns=\"http://www.w3.org/2000/svg\"> <path clip-rule=\"evenodd\" d=\"M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z\" fill=\"#F1F1F1\" fill-rule=\"evenodd\"> </path> </svg> </button> <div class=\"ncbi-header__desktop-buttons\"> <button aria-controls=\"search-field-desktop-navigation\" aria-expanded=\"false\" aria-label=\"Show search overlay\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> Search </button> <div class=\"ncbi-header__login-dropdown\"> <button aria-controls=\"login-dropdown-menu\" aria-expanded=\"false\" aria-label=\"Show login menu\" class=\"usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#person\"> </use> </svg> <span> Log in </span> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_less\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden\" role=\"graphics-symbol\"> <use xlink:href=\"/static/img/sprite.svg#expand_more\"> </use> </svg> </button> <ul class=\"usa-nav__submenu ncbi-header__login-dropdown-menu\" hidden=\"\" id=\"login-dropdown-menu\"> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__submenu-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> <li class=\"usa-nav__submenu-item\"> <button class=\"usa-button usa-button--outline ncbi-header__login-dropdown-logout-button\" type=\"button\"> Log out </button> </li> </ul> </div> </div> </div> </div> <div class=\"ncbi-search-panel ncbi--show-only-at-desktop\" hidden=\"\"> <div class=\"ncbi-search-panel__container\"> <form action=\"https://www.ncbi.nlm.nih.gov/search/all/\" aria-describedby=\"search-field-desktop-navigation-help-text\" autocomplete=\"off\" class=\"usa-search usa-search--big ncbi-search-panel__form\" method=\"GET\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field-desktop-navigation\"> Search\u2026 </label> <input class=\"usa-input\" id=\"search-field-desktop-navigation\" name=\"term\" placeholder=\"Search NCBI\" type=\"search\" value=\"\"/> <button class=\"usa-button\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label=\"Primary navigation\" class=\"usa-nav\"> <p class=\"usa-sr-only\" id=\"primary-navigation-sr-only-title\"> Primary site navigation </p> <button aria-label=\"Close navigation menu\" class=\"usa-nav__close ncbi-nav__close-button\" type=\"button\"> <img alt=\"Close\" src=\"/static/img/usa-icons/close.svg\"/> </button> <form class=\"usa-search usa-search--small ncbi--hide-at-desktop margin-top-6\" role=\"search\"> <label class=\"usa-sr-only\" for=\"search-field\"> Search </label> <input class=\"usa-input\" id=\"search-field-mobile-navigation\" name=\"search\" placeholder=\"Search NCBI\" type=\"search\"/> <button class=\"usa-button\" type=\"submit\"> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==\"/> </button> </form> <div class=\"ncbi-nav__mobile-login-menu ncbi--hide-at-desktop\" hidden=\"\"> <p class=\"ncbi-nav__mobile-login-menu-status\"> Logged in as: <strong class=\"ncbi-nav__mobile-login-menu-email\"> </strong> </p> <ul class=\"usa-nav__primary usa-accordion\"> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/\"> Dashboard </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/\"> Publications </a> </li> <li class=\"usa-nav__primary-item\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/account/settings/\"> Account settings </a> </li> </ul> </div> <button class=\"usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop\" type=\"button\"> Log in </button> </nav> </header> <section aria-label=\"PMC Header with search box\" class=\"pmc-header pmc-header--basic\"> <div class=\"pmc-nav-container\"> <div class=\"pmc-header__bar\"> <div class=\"pmc-header__logo\"> <a aria-label=\"PMC Home\" href=\"/\" title=\"Home\"> </a> </div> <button aria-label=\"Open search\" class=\"usa-button usa-button--unstyled pmc-header__search__button\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__open\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#search\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 pmc-icon__close\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"pmc-header__search\"> <form autocomplete=\"off\" class=\"usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form\" role=\"search\"> <label class=\"usa-sr-only\" for=\"pmc-search\"> Search PMC Full-Text Archive </label> <span class=\"autoComplete_wrapper flex-1\"> <input aria-autocomplete=\"both\" aria-controls=\"autoComplete_list_1\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-owns=\"autoComplete_list_1\" class=\"usa-input width-full maxw-none\" id=\"pmc-search\" name=\"term\" placeholder=\"Search PMC Full-Text Archive\" required=\"required\" role=\"combobox\" type=\"search\"/> <ul aria-label=\"Suggestions\" hidden=\"\" id=\"autoComplete_list_1\" role=\"listbox\"> </ul> </span> <button class=\"usa-button\" formaction=\"https://www.ncbi.nlm.nih.gov/pmc/\" type=\"submit\"> <span class=\"usa-search__submit-text\"> Search in PMC </span> <img alt=\"Search\" class=\"usa-search__submit-icon\" src=\"/static/img/usa-icons-bg/search--white.svg\"/> </button> </form> <ul class=\"pmc-header__search__menu\"> <li> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/advanced/\"> Advanced Search </a> </li> <li> <a class=\"usa-link\" href=\"/journals/\"> Journal List </a> </li> <li> <a class=\"usa-link\" href=\"/about/userguide/\"> User Guide </a> </li> </ul> </div> </div> </section> <div class=\"usa-section padding-top-0 desktop:padding-top-6 pmc-article-section\"> <div aria-label=\"Actions bar\" class=\"grid-container pmc-actions-bar is-not-intersecting\" role=\"complementary\"> <div class=\"grid-row\"> <div class=\"grid-col-fill display-flex\"> <div class=\"display-flex\"> <ul class=\"usa-list usa-list--unstyled usa-list--horizontal\"> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <button aria-label=\"Open resources\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#more_vert\"> </use> </svg> </button> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex mob\"> <span class=\"usa-tooltip\"> <a aria-label=\"View on publisher site\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"https://doi.org/10.1093/gpbjnl/qzae033\" rel=\"noreferrer noopener\" role=\"button\" tabindex=\"0\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> View on publisher site </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <a aria-label=\"Download PDF\" class=\"usa-link display-flex usa-tooltip__trigger\" href=\"pdf/qzae033.pdf\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> </a> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Download PDF </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty usa-tooltip__trigger\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Add to Collections </span> </span> </li> <li class=\"margin-right-2 mobile-lg:margin-right-4 display-flex\"> <span class=\"usa-tooltip\"> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button usa-button--unstyled citation-dialog-trigger display-flex usa-tooltip__trigger\" role=\"button\" tabindex=\"0\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Cite </span> </span> </li> <li class=\"pmc-permalink display-flex\"> <span class=\"usa-tooltip\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button usa-button--unstyled display-flex usa-tooltip__trigger\" tabindex=\"0\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> </button> <span aria-hidden=\"true\" class=\"usa-tooltip__body\" role=\"tooltip\"> Permalink </span> </span> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11423856/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </div> <button aria-label=\"Open article navigation\" class=\"usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-4 height-4\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#list\"> </use> </svg> </button> </div> </div> </div> <div class=\"grid-container desktop:padding-left-6\"> <div class=\"grid-row grid-gap\" id=\"article-container\"> <div class=\"grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content\"> <div class=\"grid-container padding-left-0 padding-right-0\"> <div class=\"grid-row desktop:margin-left-neg-6\"> <div class=\"grid-col-12\"> <div aria-label=\"Disclaimer note\" class=\"pmc-layout__disclaimer\" role=\"complementary\"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. <br/> Learn more: <a class=\"usa-link\" href=\"/about/disclaimer/\"> PMC Disclaimer </a> | <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright Notice </a> </div> </div> </div> <div class=\"grid-row pmc-wm desktop:margin-left-neg-6\"> <main class=\"usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0\" id=\"main-content\"> <section aria-label=\"Journal banner\" class=\"pmc-journal-banner text-center line-height-none\"> <img alt=\"Genomics, Proteomics &amp; Bioinformatics logo\" height=\"75\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-gpb.png\" usemap=\"#pmc-banner-imagemap\" width=\"500\"/> <map name=\"pmc-banner-imagemap\"> <area alt=\"Link to Genomics, Proteomics &amp; Bioinformatics\" href=\"https://doi.org/10.1093/gpbjnl/qzae033\" rel=\"noopener noreferrer\" shape=\"default\" target=\"_blank\" title=\"Link to Genomics, Proteomics &amp; Bioinformatics\"/> </map> </section> <article lang=\"en\"> <section aria-label=\"Article citation and metadata\"> <section class=\"pmc-layout__citation font-secondary font-xs\"> <div> <div class=\"display-inline-block\"> <button aria-controls=\"journal_context_menu\" aria-expanded=\"false\" class=\"cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary\" type=\"button\"> Genomics Proteomics Bioinformatics </button> </div> . 2024 Apr 18;22(2):qzae033. doi: <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/gpbjnl/qzae033\" rel=\"noopener noreferrer\" target=\"_blank\"> 10.1093/gpbjnl/qzae033 </a> </div> <nav hidden=\"hidden\" id=\"journal_context_menu\"> <ul class=\"menu-list font-family-ui\" role=\"menu\"> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/pmc/?term=%22Genomics%20Proteomics%20Bioinformatics%22%5Bjour%5D\" role=\"menuitem\"> Search in PMC </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Genomics%20Proteomics%20Bioinformatics%22%5Bjour%5D\" lang=\"en\" role=\"menuitem\"> Search in PubMed </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Genomics%20Proteomics%20Bioinformatics%22%5BTitle%20Abbreviation%5D\" role=\"menuitem\"> View in NLM Catalog </a> </li> <li role=\"presentation\"> <a class=\"usa-link\" href=\"?term=%22Genomics%20Proteomics%20Bioinformatics%22%5Bjour%5D\" role=\"menuitem\"> Add to search </a> </li> </ul> </nav> </section> <section class=\"front-matter\"> <div class=\"ameta p font-secondary font-xs\"> <hgroup> <h1> Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer </h1> </hgroup> <div class=\"cg p\"> <a aria-describedby=\"id1\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Huo%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zitian Huo </span> </a> <div hidden=\"hidden\" id=\"id1\"> <h3> <span class=\"name western\"> Zitian Huo </span> </h3> <div class=\"p\"> <sup> 1 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 2 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 3 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Huo%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zitian Huo </span> </a> </div> </div> <sup> 1, </sup> <sup> 2, </sup> <sup> 3, </sup> <sup> b </sup> , <a aria-describedby=\"id2\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Duan%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yaqi Duan </span> </a> <div hidden=\"hidden\" id=\"id2\"> <h3> <span class=\"name western\"> Yaqi Duan </span> </h3> <div class=\"p\"> <sup> 4 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 5 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 6 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Duan%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yaqi Duan </span> </a> </div> </div> <sup> 4, </sup> <sup> 5, </sup> <sup> 6, </sup> <sup> b </sup> , <a aria-describedby=\"id3\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhan%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dongdong Zhan </span> </a> <div hidden=\"hidden\" id=\"id3\"> <h3> <span class=\"name western\"> Dongdong Zhan </span> </h3> <div class=\"p\"> <sup> 7 </sup> Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhan%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dongdong Zhan </span> </a> </div> </div> <sup> 7, </sup> <sup> b </sup> , <a aria-describedby=\"id4\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xizhen Xu </span> </a> <div hidden=\"hidden\" id=\"id4\"> <h3> <span class=\"name western\"> Xizhen Xu </span> </h3> <div class=\"p\"> <sup> 8 </sup> Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20X%22%5BAuthor%5D\"> <span class=\"name western\"> Xizhen Xu </span> </a> </div> </div> <sup> 8, </sup> <sup> b </sup> , <a aria-describedby=\"id5\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20N%22%5BAuthor%5D\"> <span class=\"name western\"> Nairen Zheng </span> </a> <div hidden=\"hidden\" id=\"id5\"> <h3> <span class=\"name western\"> Nairen Zheng </span> </h3> <div class=\"p\"> <sup> 9 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20N%22%5BAuthor%5D\"> <span class=\"name western\"> Nairen Zheng </span> </a> </div> </div> <sup> 9, </sup> <sup> b </sup> , <a aria-describedby=\"id6\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Cai%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jing Cai </span> </a> <div hidden=\"hidden\" id=\"id6\"> <h3> <span class=\"name western\"> Jing Cai </span> </h3> <div class=\"p\"> <sup> 10 </sup> Institution of Pathology, The First Affiliated Hospital of Henan University, Kaifeng 475001, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Cai%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jing Cai </span> </a> </div> </div> <sup> 10 </sup> , <a aria-describedby=\"id7\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20R%22%5BAuthor%5D\"> <span class=\"name western\"> Ruifang Sun </span> </a> <div hidden=\"hidden\" id=\"id7\"> <h3> <span class=\"name western\"> Ruifang Sun </span> </h3> <div class=\"p\"> <sup> 11 </sup> Department of Tumor Biobank, Shanxi Cancer Hospital, Taiyuan 030013, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Sun%20R%22%5BAuthor%5D\"> <span class=\"name western\"> Ruifang Sun </span> </a> </div> </div> <sup> 11 </sup> , <a aria-describedby=\"id8\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jianping Wang </span> </a> <div hidden=\"hidden\" id=\"id8\"> <h3> <span class=\"name western\"> Jianping Wang </span> </h3> <div class=\"p\"> <sup> 12 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> <sup> 13 </sup> Chongqing Key Laboratory of Big Data for Bio Intelligence, School of Bioinformation, Chongqing University of Posts and Telecommunications, Chongqing 400065, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jianping Wang </span> </a> </div> </div> <sup> 12, </sup> <sup> 13 </sup> , <a aria-describedby=\"id9\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Cheng%20F%22%5BAuthor%5D\"> <span class=\"name western\"> Fang Cheng </span> </a> <div hidden=\"hidden\" id=\"id9\"> <h3> <span class=\"name western\"> Fang Cheng </span> </h3> <div class=\"p\"> <sup> 14 </sup> Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Cheng%20F%22%5BAuthor%5D\"> <span class=\"name western\"> Fang Cheng </span> </a> </div> </div> <sup> 14 </sup> , <a aria-describedby=\"id10\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zhan Gao </span> </a> <div hidden=\"hidden\" id=\"id10\"> <h3> <span class=\"name western\"> Zhan Gao </span> </h3> <div class=\"p\"> <sup> 15 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20Z%22%5BAuthor%5D\"> <span class=\"name western\"> Zhan Gao </span> </a> </div> </div> <sup> 15 </sup> , <a aria-describedby=\"id11\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20C%22%5BAuthor%5D\"> <span class=\"name western\"> Caixia Xu </span> </a> <div hidden=\"hidden\" id=\"id11\"> <h3> <span class=\"name western\"> Caixia Xu </span> </h3> <div class=\"p\"> <sup> 16 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Xu%20C%22%5BAuthor%5D\"> <span class=\"name western\"> Caixia Xu </span> </a> </div> </div> <sup> 16 </sup> , <a aria-describedby=\"id12\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D\"> <span class=\"name western\"> Wanlin Liu </span> </a> <div hidden=\"hidden\" id=\"id12\"> <h3> <span class=\"name western\"> Wanlin Liu </span> </h3> <div class=\"p\"> <sup> 17 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20W%22%5BAuthor%5D\"> <span class=\"name western\"> Wanlin Liu </span> </a> </div> </div> <sup> 17 </sup> , <a aria-describedby=\"id13\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Dong%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yuting Dong </span> </a> <div hidden=\"hidden\" id=\"id13\"> <h3> <span class=\"name western\"> Yuting Dong </span> </h3> <div class=\"p\"> <sup> 18 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 19 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Dong%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yuting Dong </span> </a> </div> </div> <sup> 18, </sup> <sup> 19 </sup> , <a aria-describedby=\"id14\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Sailong Ma </span> </a> <div hidden=\"hidden\" id=\"id14\"> <h3> <span class=\"name western\"> Sailong Ma </span> </h3> <div class=\"p\"> <sup> 20 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 21 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 22 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Ma%20S%22%5BAuthor%5D\"> <span class=\"name western\"> Sailong Ma </span> </a> </div> </div> <sup> 20, </sup> <sup> 21, </sup> <sup> 22 </sup> , <a aria-describedby=\"id15\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Q%22%5BAuthor%5D\"> <span class=\"name western\"> Qian Zhang </span> </a> <div hidden=\"hidden\" id=\"id15\"> <h3> <span class=\"name western\"> Qian Zhang </span> </h3> <div class=\"p\"> <sup> 23 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 24 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20Q%22%5BAuthor%5D\"> <span class=\"name western\"> Qian Zhang </span> </a> </div> </div> <sup> 23, </sup> <sup> 24 </sup> , <a aria-describedby=\"id16\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yiyun Zheng </span> </a> <div hidden=\"hidden\" id=\"id16\"> <h3> <span class=\"name western\"> Yiyun Zheng </span> </h3> <div class=\"p\"> <sup> 25 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Zheng%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yiyun Zheng </span> </a> </div> </div> <sup> 25 </sup> , <a aria-describedby=\"id17\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Lou%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Liping Lou </span> </a> <div hidden=\"hidden\" id=\"id17\"> <h3> <span class=\"name western\"> Liping Lou </span> </h3> <div class=\"p\"> <sup> 26 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Lou%20L%22%5BAuthor%5D\"> <span class=\"name western\"> Liping Lou </span> </a> </div> </div> <sup> 26 </sup> , <a aria-describedby=\"id18\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuang%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dong Kuang </span> </a> <div hidden=\"hidden\" id=\"id18\"> <h3> <span class=\"name western\"> Dong Kuang </span> </h3> <div class=\"p\"> <sup> 27 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuang%20D%22%5BAuthor%5D\"> <span class=\"name western\"> Dong Kuang </span> </a> </div> </div> <sup> 27 </sup> , <a aria-describedby=\"id19\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chu%20Q%22%5BAuthor%5D\"> <span class=\"name western\"> Qian Chu </span> </a> <div hidden=\"hidden\" id=\"id19\"> <h3> <span class=\"name western\"> Qian Chu </span> </h3> <div class=\"p\"> <sup> 28 </sup> Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Chu%20Q%22%5BAuthor%5D\"> <span class=\"name western\"> Qian Chu </span> </a> </div> </div> <sup> 28 </sup> , <a aria-describedby=\"id20\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Qin%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jun Qin </span> </a> <div hidden=\"hidden\" id=\"id20\"> <h3> <span class=\"name western\"> Jun Qin </span> </h3> <div class=\"p\"> <sup> 29 </sup> Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China </div> <div class=\"p\"> <sup> 30 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Qin%20J%22%5BAuthor%5D\"> <span class=\"name western\"> Jun Qin </span> </a> </div> </div> <sup> 29, </sup> <sup> 30 </sup> , <a aria-describedby=\"id21\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Guoping Wang </span> </a> <div hidden=\"hidden\" id=\"id21\"> <h3> <span class=\"name western\"> Guoping Wang </span> </h3> <div class=\"p\"> <sup> 31 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 32 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> <sup> 33 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20G%22%5BAuthor%5D\"> <span class=\"name western\"> Guoping Wang </span> </a> </div> </div> <sup> 31, </sup> <sup> 32, </sup> <sup> 33, </sup> <sup> \u2709 </sup> , <a aria-describedby=\"id22\" aria-expanded=\"false\" class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yi Wang </span> </a> <div hidden=\"hidden\" id=\"id22\"> <h3> <span class=\"name western\"> Yi Wang </span> </h3> <div class=\"p\"> <sup> 34 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"p\"> Find articles by <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D\"> <span class=\"name western\"> Yi Wang </span> </a> </div> </div> <sup> 34, </sup> <sup> \u2709 </sup> </div> <div class=\"cg p\"> Editor: <span class=\"name western\"> Minjia Tan </span> </div> <ul class=\"d-buttons inline-list\"> <li> <button aria-controls=\"aip_a\" aria-expanded=\"false\" class=\"d-button\"> Author information </button> </li> <li> <button aria-controls=\"anp_a\" aria-expanded=\"false\" class=\"d-button\"> Article notes </button> </li> <li> <button aria-controls=\"clp_a\" aria-expanded=\"false\" class=\"d-button\"> Copyright and License information </button> </li> </ul> <div class=\"d-panels font-secondary-light\"> <div class=\"d-panel p\" id=\"aip_a\"> <div class=\"p\" id=\"aff1\"> <sup> 1 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff2\"> <sup> 2 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff3\"> <sup> 3 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff4\"> <sup> 4 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff5\"> <sup> 5 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff6\"> <sup> 6 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff7\"> <sup> 7 </sup> Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China </div> <div id=\"aff8\"> <sup> 8 </sup> Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff9\"> <sup> 9 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div id=\"aff10\"> <sup> 10 </sup> Institution of Pathology, The First Affiliated Hospital of Henan University, Kaifeng 475001, China </div> <div id=\"aff11\"> <sup> 11 </sup> Department of Tumor Biobank, Shanxi Cancer Hospital, Taiyuan 030013, China </div> <div id=\"aff12\"> <sup> 12 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div id=\"aff13\"> <sup> 13 </sup> Chongqing Key Laboratory of Big Data for Bio Intelligence, School of Bioinformation, Chongqing University of Posts and Telecommunications, Chongqing 400065, China </div> <div id=\"aff14\"> <sup> 14 </sup> Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China </div> <div id=\"aff15\"> <sup> 15 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div id=\"aff16\"> <sup> 16 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div id=\"aff17\"> <sup> 17 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div id=\"aff18\"> <sup> 18 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff19\"> <sup> 19 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff20\"> <sup> 20 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff21\"> <sup> 21 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff22\"> <sup> 22 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff23\"> <sup> 23 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff24\"> <sup> 24 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff25\"> <sup> 25 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff26\"> <sup> 26 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff27\"> <sup> 27 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff28\"> <sup> 28 </sup> Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff29\"> <sup> 29 </sup> Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China </div> <div id=\"aff30\"> <sup> 30 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div id=\"aff31\"> <sup> 31 </sup> Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff32\"> <sup> 32 </sup> Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff33\"> <sup> 33 </sup> National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China </div> <div id=\"aff34\"> <sup> 34 </sup> State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China </div> <div class=\"author-notes p\"> <div class=\"fn\" id=\"qzae033-cor1\"> <sup> \u2709 </sup> <p class=\"display-inline\"> Corresponding authors: <span> wangyi@ncpsb.org.cn </span> (Wang Y), <span> wanggp@hust.edu.cn </span> (Wang G). </p> </div> <div class=\"fn\" id=\"qzae033-FM2\"> <sup> b </sup> <p class=\"display-inline\"> Zitian Huo, Yaqi Duan and Dongdong Zhan Equal contribution. </p> </div> </div> <h4 class=\"font-secondary\"> Roles </h4> <div class=\"p\"> <strong class=\"contrib\"> <span class=\"name western\"> Minjia Tan </span> </strong> : <span class=\"role\"> Handling Editor </span> </div> </div> <div class=\"d-panel p\" id=\"anp_a\"> <div class=\"notes p\"> <section class=\"history\" id=\"historyarticle-meta1\"> <p> Received 2023 Apr 17; Revised 2023 Oct 24; Accepted 2024 Jan 22; Collection date 2024 Apr. </p> </section> </div> </div> <div class=\"d-panel p\" id=\"clp_a\"> <div> \u00a9 The Author(s) 2024. Published by Oxford University Press and Science Press on behalf of the Beijing Institute of Genomics, Chinese Academy of Sciences / China National Center for Bioinformation and Genetics Society of China. </div> <p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( <a class=\"usa-link usa-link--external\" href=\"https://creativecommons.org/licenses/by/4.0/\" rel=\"noopener noreferrer\" target=\"_blank\"> https://creativecommons.org/licenses/by/4.0/ </a> ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. </p> <div class=\"p\"> <a class=\"usa-link\" href=\"/about/copyright/\"> PMC Copyright notice </a> </div> </div> </div> <div> PMCID: PMC11423856 PMID: <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/38961535/\"> 38961535 </a> </div> </div> </section> </section> <section aria-label=\"Article content\"> <section class=\"body main-article-body\"> <section class=\"abstract\" id=\"abstract1\"> <h2> <a class=\"usa-anchor\" id=\"abstract1-anchor\"> </a> Abstract </h2> <p> Small cell lung cancer (SCLC) is a highly malignant and heterogeneous cancer with limited therapeutic options and prognosis prediction models. Here, we analyzed formalin-fixed, paraffin-embedded (FFPE) samples of surgical resections by proteomic profiling, and stratified SCLC into three proteomic subtypes (S-I, S-II, and S-III) with distinct clinical outcomes and chemotherapy responses. The proteomic subtyping was an independent prognostic factor and performed better than current tumor\u2013node\u2013metastasis or Veterans Administration Lung Study Group staging methods. The subtyping results could be further validated using FFPE biopsy samples from an independent cohort, extending the analysis to both surgical and biopsy samples. The signatures of the S-II subtype in particular suggested potential benefits from immunotherapy. Differentially overexpressed proteins in S-III, the worst prognostic subtype, allowed us to nominate potential therapeutic targets, indicating that patient selection may bring new hope for previously failed clinical trials. Finally, analysis of an independent cohort of SCLC patients who had received immunotherapy validated the prediction that the S-II patients had better progression-free survival and overall survival after first-line immunotherapy. Collectively, our study provides the rationale for future clinical investigations to validate the current findings for more accurate prognosis prediction and precise treatments. </p> <section class=\"kwd-group\" id=\"kwd-group1\"> <p> <strong> Keywords: </strong> Small cell lung cancer, Proteomics, Prognosis, Chemotherapy response, Immunotherapy </p> </section> </section> <section id=\"sec1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec1-anchor\"> </a> Introduction </h2> <p> Small cell lung cancer (SCLC) is an exceptionally aggressive lung neuroendocrine neoplasm characterized by rapid tumor growth, early metastasis, and acquired chemo-resistance. Comprehensive whole-exome and whole-genome analyses have identified inactivation of <em> TP53 </em> and <em> RB1 </em> as the predominant genetic alterations in SCLC, occurring in &gt; 98% of the patients [ <a aria-describedby=\"qzae033-B1\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B1\"> 1 </a> , <a aria-describedby=\"qzae033-B2\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B2\"> 2 </a> ]. Genomic analysis of 51 SCLC cases also found genetic alterations in the PI3K/AKT/mTOR pathway in 36% of the samples, with mutations in <em> PIK3CA </em> (6%), <em> PTEN </em> (4%), <em> AKT2 </em> (9%), <em> AKT3 </em> (4%), <em> RICTOR </em> (9%), and <em> mTOR </em> (4%) [ <a aria-describedby=\"qzae033-B3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B3\"> 3 </a> ]. However, effective stratification markers and treatment targets for SCLC remain limited [ <a aria-describedby=\"qzae033-B4\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B4\"> 4 </a> ]. As a result, the overall survival (OS) of SCLC patients has seen no significant improvement despite numerous clinical trials of different chemotherapy schemes and biological agents over the past decades [ <a aria-describedby=\"qzae033-B5\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B5\"> 5 </a> ]. Moreover, a lack of biomarkers that help predict efficacy has also impeded SCLC patients from reaping significant benefits from immunotherapy [ <a aria-describedby=\"qzae033-B6\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B6\"> 6 </a> ]. Currently, the 5-year survival rate is approximately 20%\u201325% for limited-stage SCLC (LS-SCLC) and barely 1%\u20132% for extensive-stage SCLC (ES-SCLC), making SCLC one of the deadliest cancers. </p> <p> Early studies based on cell line morphologies classified SCLC into classic subtypes that expressed higher neuroendocrine markers and variant subtypes that showed low or an absence of neuroendocrine features [ <a aria-describedby=\"qzae033-B7\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B7\"> 7 </a> , <a aria-describedby=\"qzae033-B8\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B8\"> 8 </a> ]. These characteristics were further observed in clinical samples [ <a aria-describedby=\"qzae033-B9\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B9\"> 9 </a> , <a aria-describedby=\"qzae033-B10\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B10\"> 10 </a> ]. Subsequently, SCLC was classified according to the expression of neuroendocrine transcription factors ASCL1 and/or NeuroD1 [ <a aria-describedby=\"qzae033-B11\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B11\"> 11 </a> ]. Additionally, POU2F3 expression was used to define a non-neuroendocrine, tuft cell variant of SCLC [ <a aria-describedby=\"qzae033-B12\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B12\"> 12 </a> ]. And although YAP1 was proposed as a potential subtype marker for the remaining unclassified SCLC cases [ <a aria-describedby=\"qzae033-B3\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B3\"> 3 </a> ], it has yet to be confirmed [ <a aria-describedby=\"qzae033-B13\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B13\"> 13 </a> ]. Recently, re-analyzing previously published transcriptomic data classified SCLC into four subtypes [ <a aria-describedby=\"qzae033-B14\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B14\"> 14 </a> ]; in addition to the previously identified subtypes with the ASCL1 (SCLC-A), NeuroD1 (SCLC-N), and POU2F3 (SCLC-P) signatures, a new subtype (SCLC-I) characterized by the expression of inflammation gene signatures was uncovered. </p> <p> In IMpower133, a global phase I/III, double-blind, randomized, placebo-controlled trial, atezolizumab (anti-PD-L1) was added to carboplatin + etoposide for ES-SCLC. SCLC-I patients were reported to experience the greatest benefit from this combined immunotherapy and chemotherapy. In the randomized, controlled, open-label, phase III CASPIAN trial, first-line durvalumab plus platinum\u2013etoposide also significantly improved OS in patients with ES-SCLC <em> vs. </em> a clinically relevant control group [ <a aria-describedby=\"qzae033-B15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B15\"> 15 </a> ]. Additionally, cisplatin treatment of SCLC-A patient-derived xenografts (PDXs) induced intratumoral shifts toward SCLC-I [ <a aria-describedby=\"qzae033-B16\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B16\"> 16 </a> ]. These analyses suggest that the SCLC-I subtype might be the right candidate for immunotherapy. Therapeutic vulnerabilities were also identified for each subtype, including to inhibitors of PARP (SCLC-P), Aurora kinases (SCLC-N), or BCL-2 (SCLC-A) [ <a aria-describedby=\"qzae033-B16\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B16\"> 16 </a> ]. More recently, single-cell RNA sequencing (scRNA-seq) and imaging techniques have further revealed the heterogeneity and tumor microenvironment (TME) of SCLC [ <a aria-describedby=\"qzae033-B16\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B16\"> 16 </a> ]. Monocytes/macrophages appear to play a profibrotic and immunosuppressive role in SCLC TME. SCLC-N shows less immune infiltrate and greater T cell dysfunction than SCLC-A. More importantly, most SCLC cases share a small PLCG2-high subpopulation, which is linked to metastasis and poor prognosis. </p> <p> While subtyping based on genomic and transcriptomic analyses has greatly improved our understanding of SCLC, the resulting subtypes correlate poorly with clinical outcomes. In contrast, subtyping with proteomics has revealed its exceptional clinical potential for more accurate predication of prognosis, chemo-sensitivity, and treatment targets for myriad cancers including stomach [ <a aria-describedby=\"qzae033-B17\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B17\"> 17 </a> , <a aria-describedby=\"qzae033-B18\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B18\"> 18 </a> ], liver [ <a aria-describedby=\"qzae033-B19\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B19\"> 19 </a> , <a aria-describedby=\"qzae033-B20\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B20\"> 20 </a> ], ovarian carcinoma [ <a aria-describedby=\"qzae033-B21\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B21\"> 21 </a> ], colorectal cancer [ <a aria-describedby=\"qzae033-B22\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B22\"> 22 </a> ], and non-small cell lung cancer (NSCLC) [ <a aria-describedby=\"qzae033-B23\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B23\"> 23 </a> , <a aria-describedby=\"qzae033-B24\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B24\"> 24 </a> ]. Here, we reported a proteomic subtyping model derived from a discovery dataset containing 75 surgically resected formalin-fixed, paraffin-embedded (FFPE) samples. The model was then validated in an independent cohort of 52 FFPE biopsy samples. The subtypes based on our proteomic model correlated well with clinical information including OS, and also allowed subtype-specific nomination of drug targets in SCLC. In addition, analysis of another 52 samples from patients who received immunotherapy allowed us to validate the finding that one particular proteimic subtype is an immune responsive subtype. </p> </section> <section id=\"sec2\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec2-anchor\"> </a> Results </h2> <section id=\"sec3\"> <h3 class=\"pmc_sec_title\"> Limited predictive power of SCLC staging and classification systems </h3> <p> In an effort to develop a more reliable SCLC subtyping system, we first analyzed the 75 surgically resected FFPE SCLC samples as shown in <a class=\"usa-link\" href=\"#qzae033-F1\"> <strong> Figure 1 </strong> A </a> . Key clinical characteristics of the patients in the discovery cohort are presented in <a class=\"usa-link\" href=\"#qzae033-F1\"> Figure 1B </a> , with their detailed clinical and pathological data provided in <a class=\"usa-link\" href=\"#sup1\"> Table S1 </a> . Of the 75 cases, 62 (82.7%) were LS-SCLC and 13 (17.3%) were ES-SCLC according to the Veterans Administration Lung Study Group (VALG) definition. Based on the tumor\u2013node\u2013metastasis (TNM) staging system, 13 (17.3%), 19 (25.3%), 28 (37.3%) and 13 (17.3%) cases were categorized as stage I, II, III, and IV, respectively. At the end of follow-up, 31 (41.3%) patients survived, with a median OS time of 2.78 \u00b1 0.25 years. The statistically significant univariate prognostic factors included age (log-rank test, <em> P </em> = 0.035), gender (log-rank test, <em> P </em> = 0.0085), and lymph node metastasis (LNM) (log-rank test, <em> P </em> = 0.01) ( <a class=\"usa-link\" href=\"#sup1\"> Figure S1 </a> ). </p> <figure class=\"fig xbox font-sm\" id=\"qzae033-F1\"> <h4 class=\"obj_head\"> Figure 1 . </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11423856_qzae033f1.jpg\" target=\"_blank\"> <img alt=\" Figure 1 \" class=\"graphic zoom-in\" height=\"894\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f97d/11423856/ea7c2bb7b5df/qzae033f1.jpg\" width=\"699\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/qzae033-F1/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Study design and key clinical characteristics of the SCLC patients from the discovery cohort </p> <p> <strong> A </strong> . A flowchart of our study scheme. <strong> B </strong> . Clinical characteristics of the patients from the discovery cohort. <strong> C </strong> . The Kaplan\u2013Meier plots showing the limited predictive values on patient OS of the VALG, TNM, and ASCL1/NeuroD1 staging and classification methods. SCLC, small cell lung cancer; TNM, tumor\u2013node\u2013metastasis; VALG, Veterans Administration Lung Study Group; OS, overall survival; PFS, progression-free survival; ICI, immune checkpoint inhibitor; LNM, lymph node metastasis; LS, limited stage; ES, extensive stage. </p> </figcaption> </figure> <p> When the predictive value of the current staging systems (including VALG and TNM) were examined against actual prognosis of SCLC patients, their limitations became clear ( <a class=\"usa-link\" href=\"#qzae033-F1\"> Figure 1C </a> ). In fact, only TNM I patients had significantly better OS than those of TNM IV (log-rank test, <em> P </em> = 0.04) ( <a class=\"usa-link\" href=\"#qzae033-F1\"> Figure 1C </a> ). Immunohistochemistry (IHC) was used to examine the expression of ASCL1, NeuroD1, and YAP1 in the samples, and positive rates of 81.3% (61/75), 20% (15/75), and 4% (3/75), were obtained respectively. Of all cases, 11 were double-positive for ASCL1 and NeuroD1 ( <a class=\"usa-link\" href=\"#sup1\"> Figure S2 </a> ; <a class=\"usa-link\" href=\"#sup1\"> Table S1 </a> ). However, classification based on ASCL1/NeuroD1 expression did not correlate with OS differences in patients either ( <a class=\"usa-link\" href=\"#qzae033-F1\"> Figure 1C </a> ), although the NeuroD1 <sup> + </sup> /ASCL1 <sup> \u2212 </sup> subtype showed better but not statistically significant prognosis (log-rank test, <em> P </em> = 0.561). </p> </section> <section id=\"sec4\"> <h3 class=\"pmc_sec_title\"> Proteomics stratifies SCLC into subtypes that correlate with clinical outcomes </h3> <p> Since the current SCLC staging and classification systems failed to make a satisfactory prediction, we carried out a proteomic study using these 75 samples by label-free quantitative mass spectrometry (MS) ( <a class=\"usa-link\" href=\"#qzae033-F1\"> Figure 1A </a> ). We detected a total of 7028 gene products of high confidence from 75 samples, with 2957 proteins identified in more than 50% samples. The protein identities and relative abundances of each case, designated as fraction of total (FOT) [ <a aria-describedby=\"qzae033-B25\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B25\"> 25 </a> ], are provided in <a class=\"usa-link\" href=\"#sup1\"> Table S2 </a> . To develop a robust classification model, we first selected the top 1100 most abundant proteins detected from each sample, which yielded a dataset of 3460 proteins; then the 445 proteins that were detected in at least 8 samples (&gt; 10%) with the coefficient of variation (CV) greater than 1.9 were used for non-negative matrix factorization (NMF) consensus clustering ( <a class=\"usa-link\" href=\"#sup1\"> Table S3 </a> ). NMF clustering yielded three subgroups, namely S-I ( <em> n </em> = 28, 37%), S-II ( <em> n </em> = 20, 27%), and S-III ( <em> n </em> = 27, 36%) with the maximum average silhouette of 0.83 ( <a class=\"usa-link\" href=\"#qzae033-F2\"> <strong> Figure 2 </strong> A </a> ). Importantly, these proteomic subtypes correlated well with OS prognosis. Patients in S-I had the best OS with a 5-year OS probability of 75%, whereas S-III had the worst survival with only 3.7% of 5-year OS (log-rank test, <em> P </em> &lt; 0.001) ( <a class=\"usa-link\" href=\"#qzae033-F2\"> Figure 2B </a> ). A multivariate Cox analysis confirmed that the proteomic subtype was an independent prognostic factor [S-I <em> vs </em> . S-III: hazard ratio (HR) = 4.73, 95% confidence interval (CI) = 1.81\u201312.4, Cox <em> P </em> value = 0.002] after adjusting for TNM stage, VALG stage, and other covariates including chemotherapy, age, gender, LNM status, and smoking history ( <a class=\"usa-link\" href=\"#sup1\"> Figure S3 </a> ). These data indicate that proteomics-based subtyping is superior in OS prognosis. </p> <figure class=\"fig xbox font-sm\" id=\"qzae033-F2\"> <h4 class=\"obj_head\"> Figure 2 . </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11423856_qzae033f2.jpg\" target=\"_blank\"> <img alt=\" Figure 2 \" class=\"graphic zoom-in\" height=\"419\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f97d/11423856/9a73a6607367/qzae033f2.jpg\" width=\"699\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/qzae033-F2/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Proteomics stratifies SCLC into subtypes that correlate with clinical outcomes </p> <p> <strong> A </strong> . NMF clustering yielded three subgroups in SCLC in the discovery cohort. <strong> B </strong> . The three subtypes based on proteomic profiling were associated with different clinical outcomes. <strong> C </strong> . The three proteomic subtypes exhibited different responses to chemotherapy. <strong> D </strong> . The predictive classifier model showing the prognosis trend similar to the discovery cohort. In the validation cohort, biopsy samples were obtained from the First Affiliated Hospital of Henan University, China. <em> P </em> values were determined by log-rank test (*, <em> P </em> &lt; 0.05; **, <em> P </em> &lt; 0.01; ***, <em> P </em> &lt; 0.001; n.s., not significant). NMF, non-negative matrix factorization. </p> </figcaption> </figure> </section> <section id=\"sec5\"> <h3 class=\"pmc_sec_title\"> The proteomic subtypes show different benefit of chemotherapy on prognosis </h3> <p> The platinum agent (cisplatin or carboplatin) and etoposide-based combination chemotherapy is the standard care for SCLC patients after surgery, although the percentage of patients who actually benefit from such care is quite small [ <a aria-describedby=\"qzae033-B26\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B26\"> 26 </a> ]. In our dataset, approximately half of the patients ( <em> n </em> = 33, 44%) underwent chemotherapy. Considering the impact of TNM I and IV on prognosis mentioned earlier, we included only TNM II and III patients for chemo-sensitivity analysis. As shown in <a class=\"usa-link\" href=\"#qzae033-F2\"> Figure 2C </a> , chemotherapy exhibited different impacts on prognosis for the three proteomic subtypes. The S-I subtype benefited most significantly from chemotherapy (log-rank test, <em> P </em> = 0.023), with all patients who received chemotherapy still alive by the end of the study. The S-II subtype appeared to have worse prognosis (log-rank test, <em> P </em> = 0.043). The S-III subtype had the worst prognosis and was chemo-insensitive (log-rank test, <em> P </em> = 0.148). In summary, our proteomic SCLC subtyping could stratify patients into three distinct subtypes that are more clinically relevant. The S-I subtype is chemo-sensitive with the best OS. S-II has medium OS where chemotherapy might be detrimental. S-III has the poorest prognosis and is insensitive to chemotherapy, suggesting that S-III patients have the greatest need for new therapies. </p> <p> To facilitate the validation of the subtyping in the independent external dataset, we developed a random forest (RF) classifier with the discovery dataset. The top 500 most abundant proteins detected in each sample were aggregated for differential expression analysis. The resulted 58 signature proteins [fold change (FC) &gt; 1.5; adjusted <em> t </em> -test, <em> P </em> &lt; 0.05] with high identification frequencies (detected in more than 25% of the samples) were used as input (predictor variables) ( <a class=\"usa-link\" href=\"#sup1\"> Table S4 </a> ). We trained a RF classifier with a 10-fold cross-validation in the discovery dataset. Based on the 58 features, the predictive classifier model yielded a 90.8% accuracy for the discovery dataset. We collected 52 SCLC biopsy samples from another center (the First Affiliated Hospital of Henan University, Kaifeng, China) as an independent validation dataset. The corresponding clinical information of these samples is summarized in <a class=\"usa-link\" href=\"#sup1\"> Table S5 </a> . This subset included 12 female and 40 male patients, with an OS time ranging from 0.019 to 4.493 years. The 2-year survival rate was 15.4% (8/52) and the 3-year survival rate was 3.8% (2/52). Proteomic analysis was performed on the 52 biopsy samples. The results are listed in <a class=\"usa-link\" href=\"#sup1\"> Table S6 </a> . When the RF classifier was applied to the validation dataset, the predicted S-I, S-II, and S-III subtypes contained 8, 34, and 10 cases, respectively. The prognosis trend was consistent with that of the discovery cohort, with 1-year survival rates of 87.5%, 52.9%, and 30.0% and 2-year survival rates of 37.5%, 14.7%, and 0% for S-I, S-II, and S-III, respectively. Kaplan\u2013Meier analysis illustrated that the OS varied significantly among the three subtypes (log-rank test, <em> P </em> = 0.007) ( <a class=\"usa-link\" href=\"#qzae033-F2\"> Figure 2D </a> ). Thus, the proteomic subtyping model derived from surgical samples could be validated with biopsy samples from an independent cohort. </p> </section> <section id=\"sec6\"> <h3 class=\"pmc_sec_title\"> Differential signature proteins and enriched biological processes in proteomic SCLC subtypes </h3> <p> To investigate the proteomic features of SCLC subtypes, we selected significantly altered proteins by comparing their expression in each subtype to the other subtypes (FC &gt; 3 for S-I and S-II or FC &gt; 10 for S-III; Wilcox test, <em> P </em> &lt; 0.05). As a result, 206, 162, and 126 subtype-specific proteins for S-I, S-II, and S-III, respectively, were designated as significantly altered proteins ( <a class=\"usa-link\" href=\"#qzae033-F3\"> <strong> Figure 3 </strong> A </a> ; <a class=\"usa-link\" href=\"#sup1\"> Table S7 </a> ). Functional enrichment using Metascape showed that the most distinct subtype was S-II, which was significantly enriched in NABA core matrisome, interferon signaling, and immune-related processes/responses (adjusted <em> P </em> values were between 1 \u00d7 10 <sup> \u221217 </sup> and 1 \u00d7 10 <sup> \u22128 </sup> ) ( <a class=\"usa-link\" href=\"#qzae033-F3\"> Figure 3B </a> ). In the regulation of immune functions, major histocompatibility complex class I (MHC-I) molecules play an important role in cell-mediated immunity by presenting tumor antigens to CD8 <sup> + </sup> T cells and enabling cytotoxic T cells to recognize and eliminate tumor cells. Antigen presenting cells (APCs) such as B cells, dendritic cells (DCs), and monocytes/macrophages express major histocompatibility complex class II (MHC-II) molecules and present antigenic peptides to CD4 <sup> + </sup> helper T cells. Here, we found that the MHC-I molecules (including HLA-A, HLA-B, HLA-C, HLA-E, and HLA-F) but not the MHC-II molecules (including HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, and HLA-DRB5) were expressed at higher levels in S-II than in the other two subtypes ( <em> P </em> &lt; 0.05, rank sum test between two groups and Kruskal-Wallis rank sum test for all; <a class=\"usa-link\" href=\"#qzae033-F3\"> Figure 3C and D </a> ). Moreover, TAP1, TAP2, and TAPBP were also highly expressed in S-II. TAP1 and TAP2 are members of the superfamily of ATP-binding cassette (ABC) transporters that shuttle various molecules across extra-cellular and intra-cellular membranes. The ATP-loaded TAP1\u2013TAP2 complex mediates unidirectional translocation of peptide antigens from the cytosol to endoplasmic reticulum (ER) for their loading onto MHC-I molecules [ <a aria-describedby=\"qzae033-B27\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B27\"> 27 </a> ]. TAPBP is a transmembrane glycoprotein that mediates interactions between newly assembled MHC-I molecules and TAP proteins, and is required for the transport of antigenic peptides across ER membrane [ <a aria-describedby=\"qzae033-B28\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B28\"> 28 </a> ]. Thus, the S-II subtype is characterized by an enrichment of factors involved in antigen presentation. </p> <figure class=\"fig xbox font-sm\" id=\"qzae033-F3\"> <h4 class=\"obj_head\"> Figure 3 . </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11423856_qzae033f3.jpg\" target=\"_blank\"> <img alt=\" Figure 3 \" class=\"graphic zoom-in\" height=\"905\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f97d/11423856/1233943d0609/qzae033f3.jpg\" width=\"700\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/qzae033-F3/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> Differential signature proteins and enriched biological processes in proteomic SCLC subtypes </p> <p> <strong> A </strong> . Heatmap of signature proteins in each subtype. <strong> B </strong> . Metascape functional enrichment analysis identified different biological processes or pathways activated in the three subtypes. <strong> C </strong> . and <strong> D </strong> . The MHC-I (C) rather than MHC-II (D) molecules were highly expressed in S-II compared with S-I and S-III. <em> P </em> values were determined by rank sum test between two groups and Kruskal-Wallis rank sum test for all. MHC-I, major histocompatibility complex class I; MHC-II, major histocompatibility complex class II; FOT, fraction of total. </p> </figcaption> </figure> <p> The S-I subtype appeared to be marginally enriched in proteins functioning in transport, membrane trafficking, and RNA metabolic processes (adjusted <em> P </em> values of 1 \u00d7 10 <sup> \u22124 </sup> \u20131 \u00d7 10 <sup> \u22122 </sup> ). Detailed analysis identified ubiquitin-mediated proteolysis in cell cycle control, including the anaphase promoting complex (ANAPC1, ANAPC13, and ANAPC4) and COPS9 signalosome components (COPS3 and COPS7B) as well as NEDD8. DNA repair and DNA replication proteins, including MSH3, LIG1, POLE3, RFC3, ORC2, and ATM, were also enriched ( <a class=\"usa-link\" href=\"#sup1\"> Table S7 </a> ). After adjusting for <em> P </em> values, Metascape analysis could not identify significantly enriched biological processes for S-III. Manual inspection showed that proteins in chromatin organization/transcription regulation as well as various enzymes were enriched ( <a class=\"usa-link\" href=\"#sup1\"> Table S7 </a> ). Among them were proteins mediating chromatin assembly and telomere maintenance (CHAF1A, TERF2, and TOX4), transcription coactivators ( <em> e.g. </em> , ATAD2, ZNF516, PHF6, PHF8, MED6, TAF5, and TAF), and transcription corepressors ( <em> e.g. </em> , TBL1X, TBL1Y, CHD8, ATXN2, and SPEN). It appears that mis-regulation in chromatin structure and transcription may profoundly impact an array of biological processes, which the Metascape algorithm might have failed to identify. </p> </section> <section id=\"sec7\"> <h3 class=\"pmc_sec_title\"> The S-II patients have the best immunotherapy responses in SCLC </h3> <p> Aforementioned analyses suggest that S-II is an inflamed SCLC subtype in nature, which may benefit from immunotherapy. To test this hypothesis, we collected another 52 real-world FFPE biopsy or surgery samples from ES-SCLC patients who received immune checkpoint inhibitors (ICIs; including sintilimab, toripalimab, durvalumab, camrelizumab, tislelizumab, and atezolizumab), termed as the ICI cohort. Among these samples, 37 were treated with combined immunotherapy with chemotherapy as a first-line treatment, and 49 were from biopsy ( <a class=\"usa-link\" href=\"#qzae033-F4\"> <strong> Figure 4 </strong> A </a> ; <a class=\"usa-link\" href=\"#sup1\"> Table S8 </a> ). We classified these samples using the model derived from the discovery dataset ( <a class=\"usa-link\" href=\"#sup1\"> Table S9 </a> ) into S-I (23 patients), S-II (13 patients), and S-III (16 patients). We specified an ICI progression-free survival (ICI-PFS) as the duration between the time when the first immunotherapy was applied, and progressive disease (PD) was determined by clinical standards. As shown in <a class=\"usa-link\" href=\"#qzae033-F4\"> Figure 4B and C </a> , the ICI-PFS of the S-II patients with first-line ICIs rather than &gt; first-line ICIs was longer than that of S-III (log-rank test, <em> P </em> = 0.038) and S-I (log-rank test, <em> P </em> = 0.056). Moreover, when the Kaplan\u2013Meier plots of the S-II patients in the ICI cohort, the discovery cohort (WH-S-II, no immunotherapy), and the validation cohort (HN-S-II, no immunotheray) were compared, the S-II patients treated with ICIs achieved better OS (ICI cohort <em> vs. </em> discovery cohort: <em> P </em> = 0.03; ICI cohort <em> vs. </em> validation cohort: <em> P </em> &lt; 0.0001; log-rank test) ( <a class=\"usa-link\" href=\"#qzae033-F4\"> Figure 4D </a> ). Together, these analyses demonstrate the values of stratifying patients for immunotherapy, and suggest that immunotherapy could significantly improve the OS of SCLC patients, particularly for those in the S-II subtype. </p> <figure class=\"fig xbox font-sm\" id=\"qzae033-F4\"> <h4 class=\"obj_head\"> Figure 4 . </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11423856_qzae033f4.jpg\" target=\"_blank\"> <img alt=\" Figure 4 \" class=\"graphic zoom-in\" height=\"414\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f97d/11423856/55d45ca1fc59/qzae033f4.jpg\" width=\"700\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/qzae033-F4/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> The S-II subtype patients are more likely to benefit from immunotherapies </p> <p> <strong> A </strong> . The clinical characteristics of the patients from the ICI cohort. <strong> B </strong> . and <strong> C </strong> . In the ICI cohort, the S-II patients had the best PFS time when receiving first-line immunotherapy (B) but showed no statistically obvious difference compared with S-I/S-III patients when receiving second-line immunotherapy (C). <strong> D </strong> . In all S-II patients, patients after immunotherapy had better OS than those without immunotherapy. S-II patients in the ICI cohort and S-II patients who did not receive immunotherapy in the discovery and validation cohorts were used for analysis. <em> P </em> values were determined by log-rank test (*, <em> P </em> &lt; 0.05; ****, <em> P </em> &lt; 0.0001; n.s., not significant). </p> </figcaption> </figure> </section> <section id=\"sec8\"> <h3 class=\"pmc_sec_title\"> Potential drug repurposing targets for S-III subtype patients </h3> <p> Since patients in the S-III subtype had the worst OS and did not benefit from chemotherapy, they were the most in need of new therapeutic options. We selected specifically overexpressed proteins in S-III compared with S-I and S-II and investigated their feasibility as potential drug repurposing targets. We first identified previously investigated actionable drug targets and found that at least one target among EGFR, AURKB, BCL-2, and EZH2 was highly expressed in 77.8% (21/27) of the S-III patients. Drugs targeting AURKB, BCL-2, or EZH2 are currently in various stages of clinical development and have shown promising results for treating certain cancers [ <a aria-describedby=\"qzae033-B29\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B29\"> 29 </a> , <a aria-describedby=\"qzae033-B30\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B30\"> 30 </a> ]. Many kinases, phosphatases, transporters, ubiquitin\u2013proteasome system (UPS) proteins, and other enzymes were overexpressed in S-III, accounting for nearly 1/3 of all specifically overexpressed proteins in S-III. Proteins that regulate necroptosis, including MLKL, TRAF2, and RIPK1, are also potential targets [ <a aria-describedby=\"qzae033-B31\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B31\"> 31 </a> ]. Their druggability needs to be further investigated. An overview of the potential drug repurposing targets for each individual patient is shown in <a class=\"usa-link\" href=\"#qzae033-F5\"> <strong> Figure 5 </strong> </a> . </p> <figure class=\"fig xbox font-sm\" id=\"qzae033-F5\"> <h4 class=\"obj_head\"> Figure 5 . </h4> <p class=\"img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center\"> <a class=\"tileshop\" href=\"https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11423856_qzae033f5.jpg\" target=\"_blank\"> <img alt=\" Figure 5 \" class=\"graphic zoom-in\" height=\"331\" loading=\"lazy\" src=\"https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f97d/11423856/b5b9ce80a782/qzae033f5.jpg\" width=\"699\"/> </a> </p> <div class=\"p text-right font-secondary\"> <a class=\"usa-link\" href=\"figure/qzae033-F5/\" rel=\"noopener noreferrer\" target=\"_blank\"> Open in a new tab </a> </div> <figcaption> <p> The atlas of potential drug targets for individual patients in S-III </p> <p> FC, fold change; UPS, ubiquitin\u2013proteasome system. </p> </figcaption> </figure> </section> </section> <section id=\"sec9\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec9-anchor\"> </a> Discussion </h2> <p> While genomic and transcriptomic analyses have greatly improved our understanding of SCLC tumorigenesis, their values in identifying effective stratification markers and therapeutic targets are limited. In this retrospective proteomic analysis, we showed that proteomics alone could stratify SCLC for prognosis and chemo-sensitivity. Since most SCLC tumors are non-resectable when diagnosed, we validated our proteomic subtyping using biopsy samples from an independent center, expanding the clinical utility of our proteomic subtyping method. Our analysis showed that all S-I patients in the discovery cohort who received chemotherapy were alive by the end of the study, confirming the suitability of chemotherapy as first-line treatment option for these patients. Antigen presentation and other immune responses were enriched in S-II, suggesting that ICIs may be a viable choice for S-II patients. We validated this prediction in a third independent group of patients that received immunotherapy as the first-line treatment. Notably, a previous transcriptomic study also defined an \u201cinflamed\u201d SCLC subtype (SCLC-I) [ <a aria-describedby=\"qzae033-B15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B15\"> 15 </a> ] which was characterized by high expression of genes related to HLAs and experienced greatest benefit from the addition of anti-PD-L1 to chemotherapy [ <a aria-describedby=\"qzae033-B15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B15\"> 15 </a> ]. Our proteomic subtyping thus may provide value in guiding SCLC treatment. </p> <p> Since neither PD-L1 expression nor TMB is a reliable biomarker for the prediction of immunotherapy response in clinical trials such as IMpower133 and CheckMate-032, other biomarkers are in great need. Our analysis showed that patients in the S-II subtype may benefit from the immunotherapy. Although they were mostly ES-SCLC and lost the oppotunity for surgery, the 2-year survival rate of the S-II patients with immunotherapy reached over 30%, much better than the other subtypes. In other clinical trials ( <em> e.g. </em> , ASTRUM-005), the median PFS was generally less than 6 months [ <a aria-describedby=\"qzae033-B32\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B32\"> 32 </a> ], which was similar to that of S-I/S-III patients in our study. However, the median PFS reached around one year for the S-II subtype here. It will be important to investigate in a prospective trial to determine whether the S-II subtype could serve as a new predictive biomarker for guiding SCLC immunotherapy. </p> <p> Mechanisms of immune resistance vary [ <a aria-describedby=\"qzae033-B33\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B33\"> 33 </a> ]. MHC-I molecules were generally expressed at low levels in the SCLC tumor cells, resulting in low antigen presentation. In addition, tumor cells can also secrete factors to inhibit antigen presenting cells. About 50% of patients with SCLC have almost no T cell infiltration, and there are also suppressive immune cells in the immune microenvironment of SCLC. In our study, S-II subtype had higher MHC-I molecules along with other proteins in antigen presenting. Interferon gamma signaling was also enriched in S-II. Thus, S-II may be the immune hot subtype while S-I and S-III were the cold ones. </p> <p> Among proteins and pathways as potential drug targets for the S-III subtype, BCL-2, EZH2, ARUKB, and EGFR are actionable drug targets that have been at various stages of clinical trials. Among them, EZH2 was identified as an upstream regulator in the SLFN11 axis that mediates acquired chemoresistance in an <em> in vitro </em> PDX model [ <a aria-describedby=\"qzae033-B34\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B34\"> 34 </a> ]. Food And Drug Administration (FDA) has recently approved the EZH2 inhibitor tazemetostat for treating epithelioid sarcoma [ <a aria-describedby=\"qzae033-B35\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B35\"> 35 </a> ]. Interestingly, EZH2 is a negative regulator of MHC-I molecules, and inhibiting EZH2 could enhance antigen presentation and circumvent anti-PD-1 resistance [ <a aria-describedby=\"qzae033-B36\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B36\"> 36 </a> ]. Although EGFR tyrosine kinase inhibitors (EGFR-TKIs; such as gefitinib) are not effective in a SCLC clinical trial [ <a aria-describedby=\"qzae033-B37\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B37\"> 37 </a> ], the identification of a subgroup of patients with EGFR overexpression suggest an alternative approach by using EGFR antibody. Notably, EGFR antibody has been approved as first-line treatment option for KRAS wild-type, EGFR-overexpressing colon cancer patients [ <a aria-describedby=\"qzae033-B38\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B38\"> 38 </a> ]. BCL-2 family proteins comprise the sentinel network that regulates mitochondrial and intrinsic apoptotic responses. Previous studies of a BCL-2 inhibitor fell short of expectations in SCLC clinical trials [ <a aria-describedby=\"qzae033-B39\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B39\"> 39 </a> ]. A possible explanation is that patients in the trial were not screened for BCL-2 expression. Interestingly, the SCLC-A transcriptomic subtype [ <a aria-describedby=\"qzae033-B15\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B15\"> 15 </a> ], which had higher expression of BCL-2, was found to be sensitive to multiple BCL-2 inhibitors in an <em> in vitro </em> study. Recently, the single target BCL-2 inhibitor venetoclax, which was approved by the FDA for acute myeloid leukemia and chronic lymphocytic leukemia [ <a aria-describedby=\"qzae033-B40\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B40\"> 40 </a> ], showed therapeutic effect on multiple PDXs of SCLC [ <a aria-describedby=\"qzae033-B41\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B41\"> 41 </a> ]. AURKB is a mitotic protein kinase. Phase I/II clinical studies of its inhibitor alisertib have demonstrated increased antitumor effects in various hematologic malignancies and solid tumors [ <a aria-describedby=\"qzae033-B42\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B42\"> 42 </a> ]. </p> <p> In addition, our proteomic data suggest that necroptosis regulators including MLKL, TRAF2, and RIPK1 may be investigated as potential therapeutic targets for SCLC. Necroptosis causes cellular swelling and plasma membrane collapse, which may lead to the release of intra-cellular biomolecules including damage-associated molecular patterns (DAMPs) and cytokines. These molecules can perform immunological functions such as chemotaxis, phagocytosis, and immune cell activation [ <a aria-describedby=\"qzae033-B43\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B43\"> 43 </a> ]. Although initial attraction of antigen presentation cells such as macrophages and DCs by DAMPs/cytokines could recruit CD8 <sup> + </sup> /CD4 <sup> + </sup> T cells for immune activation in early stage, the recruitment of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) at later stages could lead to immune suppression [ <a aria-describedby=\"qzae033-B44\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B44\"> 44 </a> ]. The effects of necroptosis proteins on tumors are cancer dependent. Cytokines released by necroptotic cancer cells can promote tumor angiogenesis, proliferation, and metastasis. For instance, high expression of RIPK1 was linked to metastasis in breast cancer [ <a aria-describedby=\"qzae033-B45\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B45\"> 45 </a> ] and poor survival in glioblastoma [ <a aria-describedby=\"qzae033-B46\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B46\"> 46 </a> ], but was a good prognostic indicator in head and neck cancer [ <a aria-describedby=\"qzae033-B47\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B47\"> 47 </a> ]. High MLKL expression correlated positively with good prognosis in colorectal cancer [ <a aria-describedby=\"qzae033-B48\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B48\"> 48 </a> ], high-risk human papillomavirus (HR-HPV) cervical cancer [ <a aria-describedby=\"qzae033-B49\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B49\"> 49 </a> ], ovarian cancer [ <a aria-describedby=\"qzae033-B50\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B50\"> 50 </a> ], and pancreatic adenocarcinoma [ <a aria-describedby=\"qzae033-B51\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B51\"> 51 </a> ], but negatively with breast cancer [ <a aria-describedby=\"qzae033-B52\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B52\"> 52 </a> ], cervical squamous cell carcinoma [ <a aria-describedby=\"qzae033-B53\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B53\"> 53 </a> ], and gastric cancer [ <a aria-describedby=\"qzae033-B54\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B54\"> 54 </a> ]. We found in this study a correlation between high expression of MLKL, TRAF2, and RIPK1 and the most malignant SCLC S-III subtype, suggesting that these proteins may represent good targets for treating SCLC. </p> <p> The S-III subtype is also enriched for proteins involved in chromatin organization and transcriptional regulation. For example, CHAF1A, TERF2, and TOX4 can mediate chromatin assembly, protect chromosome ends, and regulate chromatin binding during DNA replication [ <a aria-describedby=\"qzae033-B55\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B55\"> 55 </a> ], metaphase [ <a aria-describedby=\"qzae033-B56\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B56\"> 56 </a> ], and transition to interphase [ <a aria-describedby=\"qzae033-B57\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B57\"> 57 </a> ], respectively. For transcriptional regulation, ATAD2 and ZNF516 act as transcription activators, promoting the expression of CCND1/MYC/E2F1 [ <a aria-describedby=\"qzae033-B58\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B58\"> 58 </a> ] or genes related to cellular response to replication stress [ <a aria-describedby=\"qzae033-B59\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B59\"> 59 </a> ], respectively. Moreover, PHF8 acts as a coactivator of ribosomal DNA (rDNA) transcription by activating polymerase I-mediated transcription of ribosomal RNA (rRNA) genes [ <a aria-describedby=\"qzae033-B60\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B60\"> 60 </a> ], while MED6 is a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes [ <a aria-describedby=\"qzae033-B61\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B61\"> 61 </a> ]. These findings underline the importance of investigating dysfunctional chromatin organization in the development and treatment of SCLC. </p> <p> Our study has some limitations. For example, our discovery cohort was relatively small compared with other omics studies, such as those of NSCLC. This is in part because most SCLC cases were detected at late stages without opportunity for surgery, so large-scale proteomic analysis of surgically resected samples was rare in the past. Moreover, our proteomic stratification was different from previous transcriptional classification based on ASCL1, NeuroD1, and YAP1, thus providing limited mechanistic insight into the tumorigenesis. The reason for the discrepancy is unclear, but we did notice the overlap of several of these markers by IHC. </p> <p> In summary, our results demonstrate the validity and importance of using both surgical and biopsy FFPE samples and serve as a valuable resource for the SCLC research community. This work should also help guide future pre-clinical investigations that seek more meaningful and efficacious stratification of SCLC in order to improve therapeutic responses and patient survival. </p> </section> <section id=\"sec10\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec10-anchor\"> </a> Materials and methods </h2> <section id=\"sec11\"> <h3 class=\"pmc_sec_title\"> Sample collection </h3> <p> Tumors in the discovery cohort (diagnosed from 2012 to 2018) were obtained with informed consent from archival sources at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Tumors in the second cohort (diagnosed from 2018 to 2021) were biopsy samples obtained from the First Affiliated Hospital of Henan University, Kaifeng, China. The 52 samples in the ICI cohort was also from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (diagnosed from 2017 to 2021). The samples were collected from patients at initial diagnosis. All diagnoses were independently reviewed by three experienced pathologists, and complied with the latest World Health Organization classification standards. The tumors came from patients not treated with neoadjuvant chemotherapy or radiotherapy before operation, with no previous history of malignancy, having SCLC as the initial primary cancer diagnosis at the time of surgical resection, and with adequate tumor/tissue material as well as clinical annotation and follow-up time. The tumor cell content was &gt; 90% tumor cells judged by haematoxylin and eosin (H&amp;E) staining and yielded &gt; 700 proteins in MS analysis. All cases were staged according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for SCLC (version 4.2020). </p> </section> <section id=\"sec12\"> <h3 class=\"pmc_sec_title\"> IHC and assessment </h3> <p> Immunohistochemical staining was conducted using tissue arrays. Prior to deparaffinization, the slides were heated to 60\u00b0C for 10 min to melt the paraffin. The slides were then washed three times with xylene to solubilize and remove the paraffin. Next, the xylene was removed by washing three times with 100% ethanol followed by 75% ethanol, 50% ethanol, and phosphate buffer saline (PBS). After the sections were deparaffinized and hydrated, the endogenous peroxidase activity was blocked. Antigen retrieval was performed using the Dako Target Retrieval Solution, High pH (Catalog No. S1699, Agilent Technologies, Santa Clara, CA) on Dako Ominis (Agilent Technologies) at 98\u00b0C for 25 min. The slides were then incubated with the primary antibody at 4\u00b0C overnight. </p> <p> Primary antibodies used in this study were: anti-ASCL1 antibody (1:200; Catalog No. ab211327, Abcam, Boston, MA), anti-NeuroD1 antibody (1:200; Catalog No. ab213725, Abcam), and anti-YAP1 antibody (1:50; Catalog No. ab52771, Abcam). After incubated with the secondary antibody of Universal SAP reagent kit (mouse/rabbit universal) (Catalog No. SAP-9100, Zhongshan Biotechnology, Beijing, China) for \u223c 1 h, the sections were visualized with the DAB kit (Catalog No. ZLI-9017, Zhongshan Biotechnology) and counterstained with hematoxylin. The stained samples were scored by three pathologists independently for the multiplication of staining intensity (1, weak; 2, moderate; 3, strong) and the percentage of positive tumor cells, which resulted in scores of 0\u2013300. A score of &lt; 10 was designated as 0, 10\u201340 as 1+, 41\u2013140 as 2+, and 141\u2013300 as 3+. All samples with scores of &gt; 10 were considered positive cases. </p> </section> <section id=\"sec13\"> <h3 class=\"pmc_sec_title\"> Protein extraction, trypsin digestion, and liquid chromatography-tandem mass spectrometry processing </h3> <p> For each SCLC sample, proteins were extracted from three tissue slices (5-\u00b5m thick) from the FFPE block (2\u20135 mm in diameter). The deparaffinization procedure was the same as IHC as described above. Air dried sample was scraped from the slide and resolubilized in 100 ml of 50 mM NH <sub> 4 </sub> HCO <sub> 3 </sub> . The sample was then incubated at 95\u00b0C for 5 min for de-crosslinking, and cooled to room temperature. Trypsin digestion was carried out at 37\u00b0C overnight. Peptides were extracted twice with 200 \u00b5l of extraction buffer (50% acetonitrile and 0.1% formic acid in water) with 15 min vortex. The resulting peptides were dried and stored at \u221280\u00b0C for future analysis. The digested peptides were eluted, divided into three fractions, and analyzed on a Q Exactive HF-X (Catalog No. 2151480, Thermo Fisher Scientific, Waltham, MA) or Orbitrap Exploris 480 Mass Spectrometer (Catalog No. BRE725539, Thermo Fisher Scientific) coupled with an UltiMate 3000 RSLCnano LC system (Catalog No. 5200.0356, Thermo Fisher Scientific) and operated at data-dependent aquisition mode. MS1 was measured in the Orbitrap at a resolution of 60,000 followed by tandem MS scans of the top 40 precursors using higher-energy collision dissociation with 27% of normalized collision energy and 15 s of dynamic exclusion time. </p> </section> <section id=\"sec14\"> <h3 class=\"pmc_sec_title\"> MS data analysis </h3> <p> MS raw files were searched against the National Center for Biotechnology Information (NCBI) RefSeq human proteome database (updated on 04/07/2013, 27,414 entries) in Firmiana [ <a aria-describedby=\"qzae033-B62\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B62\"> 62 </a> ], a one-stop proteomic cloud platform for data processing and analysis, implemented with Mascot search engine with Percolator (Matrix Science, version 2.3.01). The following search parameters were used: (1) mass tolerances were 20 ppm for precursor ions and 0.05 Da for product ions; (2) up to two missed cleavages were allowed; (3) the minimal peptide length was seven amino acids; (4) cysteine carbamidomethylation was set as a fixed modification, and N-acetylation and methionine oxidation were considered variable modifications; and (5) the charges of precursor ions were limited to +2, +3, +4, +5, and +6. The peptide and protein false discovery rates (FDRs) were both set to 1%. A label-free, intensity-based absolute quantification (iBAQ) algorithm was used for protein quantification. The iBAQ values were calculated by dividing the raw intensities by the number of theoretical observable peptides. FOT, calculated by dividing a protein\u2019s iBAQ by the sum of iBAQs of all identified proteins in a single experiment, was used as normalized abundance to compare protein abundance across all experiments. The missing value was imputed with 1/10 of the global non-zero minimum value of the sample [ <a aria-describedby=\"qzae033-B63\" aria-expanded=\"false\" class=\"usa-link\" href=\"#qzae033-B63\"> 63 </a> ]. </p> </section> <section id=\"sec15\"> <h3 class=\"pmc_sec_title\"> Subtyping and validation </h3> <p> A NMF consensus clustering algorithm was used for subtyping the discovery dataset. The standard \u201cbrunet\u201d option was selected and 50 iterations were performed. The number of clusters ( <em> k </em> ) was set as 2 to 6, and the minimum member of each subclass was set as 10. The silhouette indicator (average silhouette &gt; 0.8) and prognostic association ( <em> P </em> &lt; 0.01) were used to determine the optimal clustering number. </p> <p> To develop a robust classification model, we first selected the top 1100 most abundant proteins detected from each sample, which yielded a dataset of 3460 proteins; then the 445 proteins that were detected in at least 8 samples (&gt; 10%) with the CV greater than 1.9 were used for NMF consensus clustering ( <a class=\"usa-link\" href=\"#sup1\"> Table S3 </a> ). </p> <p> To validate the classification in an independent external dataset, the RF classifier was implemented on the discovery dataset using the R package randomForest. The top 500 most abundant proteins detected in each sample were aggregated for differential expression analysis. Finally, 58 significantly differentially expressed proteins (FC &gt; 1.5; adjusted <em> t </em> -test, <em> P </em> &lt; 0.05) with high identification frequencies (detected in more than 25% of the samples) were used as input (predictor variables). The subtype terms of SCLC on the discovery dataset were used as the response variables. The optimal parameters were estimated from the R function training with package caret. The 10-fold cross-validation strategy was utilized for internal validation. </p> </section> <section id=\"sec16\"> <h3 class=\"pmc_sec_title\"> Survival analysis </h3> <p> The Kaplan\u2013Meier method, log-rank test, and the Cox proportional-hazards model with Wald statistics were used for survival analysis in all datasets. The multivariate Cox analysis was adjusted for age, sex, staging system, and chemotherapy. HRs with 95% CI were estimated for each variable. All calculated <em> P </em> values were two-sided where <em> P </em> &lt; 0.05 was considered statistically significant. </p> </section> <section id=\"sec17\"> <h3 class=\"pmc_sec_title\"> Bioinformatic analysis </h3> <p> To investigate the proteomic features of SCLC subtypes, we selected significantly altered proteins by comparing their expression in each subtype to the other subtypes (FC &gt; 3 for S-I and S-II or FC &gt; 10 for S-III; Wilcox test, <em> P </em> &lt; 0.05). Metascape analysis was conducted online ( <a class=\"usa-link usa-link--external\" href=\"https://metascape.org\" rel=\"noopener noreferrer\" target=\"_blank\"> https://metascape.org </a> ) for functional pathway analysis. The on-line tool SangerBox ( <a class=\"usa-link usa-link--external\" href=\"http://www.sangerbox.com/tool.html\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.sangerbox.com/tool.html </a> ) was used for generating the plots and heatmap. All other statistical analyses were carried out with R 3.6.1. </p> </section> </section> <section id=\"sec18\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec18-anchor\"> </a> Ethical statement </h2> <p> This study was approved by the ethical committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China (Approval No. TJ-IRB20201011). The written informed consent was obtained from the participating patients. </p> </section> <section id=\"sec19\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec19-anchor\"> </a> Supplementary Material </h2> <section class=\"sm xbox font-sm\" id=\"sup1\"> <div class=\"caption p\"> <span> qzae033_Supplementary_Data </span> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11423856/bin/qzae033_supplementary_data.zip\"> qzae033_supplementary_data.zip </a> <sup> (37.5MB, zip) </sup> </div> </div> </section> </section> <section class=\"ack\" id=\"ack1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ack1-anchor\"> </a> Acknowledgments </h2> <p> This work was supported by the National Key R&amp;D Program of China (Grant Nos. 2018YFA0507503, 2017YFA0505102, 2017YFA0505103, and 2017YFA0505104), the National Natural Science Foundation of China (Grant Nos. 82072597, 62131009, 31770892, 31970725, 31870828, 81874237, and 81974016), the Beijing Municipal Natural Science Foundation (Grant No. 7192199), the State Key Laboratory of Proteomics (Grant No. SKLP-K202002), the Kaifeng Science and Technology Development Plan Project (Grant No. 1806005), China. We thank the Mass Spectrometry Platform of National Center for Protein Sciences (Beijing) (PHOENIX Center) for technical assistance. We also thank all the patients who participated in this study, as well as the clinicians and staff of the institutions who assisted with the studies. </p> </section> <section class=\"contrib-info\" id=\"_ci93_\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"_ci93_-anchor\"> </a> Contributor Information </h2> <p> Zitian Huo, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Yaqi Duan, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Dongdong Zhan, Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China. </p> <p> Xizhen Xu, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Nairen Zheng, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China. </p> <p> Jing Cai, Institution of Pathology, The First Affiliated Hospital of Henan University, Kaifeng 475001, China. </p> <p> Ruifang Sun, Department of Tumor Biobank, Shanxi Cancer Hospital, Taiyuan 030013, China. </p> <p> Jianping Wang, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China; Chongqing Key Laboratory of Big Data for Bio Intelligence, School of Bioinformation, Chongqing University of Posts and Telecommunications, Chongqing 400065, China. </p> <p> Fang Cheng, Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China. </p> <p> Zhan Gao, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China. </p> <p> Caixia Xu, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China. </p> <p> Wanlin Liu, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China. </p> <p> Yuting Dong, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Sailong Ma, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Qian Zhang, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Yiyun Zheng, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Liping Lou, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Dong Kuang, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Qian Chu, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Jun Qin, Beijing Pineal Diagnostics Co., Ltd., Beijing 102206, China; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China. </p> <p> Guoping Wang, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; National Health Commission Key Laboratory of Respiratory Diseases, Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. </p> <p> Yi Wang, State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China. </p> </section> <section id=\"sec20\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec20-anchor\"> </a> Data availability </h2> <p> All data and search results have been deposited to the iProX database (iProX: IPX0004230000), which are publicly accessible at <a class=\"usa-link usa-link--external\" href=\"http://www.iprox.org\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.iprox.org </a> . </p> </section> <section id=\"sec21\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec21-anchor\"> </a> CRediT author statement </h2> <p> <strong> Zitian Huo: </strong> Writing \u2013 original draft, Formal analysis, Investigation, Visualization. <strong> Yaqi Duan: </strong> Writing \u2013 review &amp; editing, Methodology. <strong> Dongdong Zhan: </strong> Investigation, Data curation, Validation. <strong> Xizhen Xu: </strong> Visualization, Writing \u2013 review &amp; editing. <strong> Nairen Zheng: </strong> Data curation, Validation. <strong> Jing Cai: </strong> Data curation, Resources. <strong> Ruifang Sun: </strong> Resources, Data curation. <strong> Jianping Wang: </strong> Resources, Data curation. <strong> Fang Cheng: </strong> Resources, Data curation. <strong> Zhan Gao: </strong> Resources, Data curation. <strong> Caixia Xu: </strong> Resources, Data curation. <strong> Wanlin Liu: </strong> Resources, Data curation. <strong> Yuting Dong: </strong> Resources, Data curation. <strong> Sailong Ma: </strong> Resources. <strong> Qian Zhang: </strong> Resources. <strong> Yiyun Zheng: </strong> Resources. <strong> Liping Lou: </strong> Resources. <strong> Dong Kuang: </strong> Writing \u2013 review &amp; editing. <strong> Qian Chu: </strong> Supervision, Project administration, Funding acquisition. <strong> Jun Qin: </strong> Conceptualization, Resources, Supervision, Project administration, Funding acquisition, Writing \u2013 review &amp; editing. <strong> Guoping Wang: </strong> Conceptualization, Resources, Supervision, Project administration, Funding acquisition. <strong> Yi Wang: </strong> Conceptualization, Resources, Supervision, Project administration, Funding acquisition, Writing \u2013 review &amp; editing. All authors have read and approved the final manuscript. </p> </section> <section id=\"sec22\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec22-anchor\"> </a> Supplementary material </h2> <p> <a class=\"usa-link\" href=\"#sup1\"> Supplementary material </a> is available at <em> Genomics, Proteomics &amp; Bioinformatics </em> online ( <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/gpbjnl/qzae033\" rel=\"noopener noreferrer\" target=\"_blank\"> https://doi.org/10.1093/gpbjnl/qzae033 </a> ). </p> </section> <section id=\"sec23\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec23-anchor\"> </a> Competing interests </h2> <p> Jun Qin and Yi Wang are cofounders and co-owners of the Beijing Pineal Diagnostics Co., Ltd., and Dongdong Zhan and Fang Cheng are employees of the Beijing Pineal Diagnostics Co., Ltd. All the other authors have declared no competing interests. </p> </section> <section id=\"sec24\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"sec24-anchor\"> </a> ORCID </h2> <p> 0000-0002-7368-0831 (Zitian Huo) </p> <p> 0000-0002-2392-5642 (Yaqi Duan) </p> <p> 0000-0002-0704-8782 (Dongdong Zhan) </p> <p> 0009-0000-3222-6862 (Xizhen Xu) </p> <p> 0000-0002-3952-1570 (Nairen Zheng) </p> <p> 0000-0001-8002-2645 (Jing Cai) </p> <p> 0000-0002-4791-3734 (Ruifang Sun) </p> <p> 0000-0001-6142-7153 (Jianping Wang) </p> <p> 0000-0001-9385-204X (Fang Cheng) </p> <p> 0009-0001-9697-6547 (Zhan Gao) </p> <p> 0009-0003-1014-1448 (Caixia Xu) </p> <p> 0000-0002-4116-2597 (Wanlin Liu) </p> <p> 0000-0003-0886-9221 (Yuting Dong) </p> <p> 0009-0007-5118-6991 (Sailong Ma) </p> <p> 0000-0002-0869-3951 (Qian Zhang) </p> <p> 0000-0001-8103-3688 (Yiyun Zheng) </p> <p> 0000-0002-9542-568X (Liping Lou) </p> <p> 0000-0001-9558-0333 (Dong Kuang) </p> <p> 0000-0001-8192-7630 (Qian Chu) </p> <p> 0000-0003-3769-3720 (Jun Qin) </p> <p> 0009-0000-6472-0849 (Guoping Wang) </p> <p> 0000-0002-2088-2085 (Yi Wang) </p> </section> <section class=\"ref-list\" id=\"ref1\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"ref1-anchor\"> </a> References </h2> <section id=\"ref1_sec2\"> <ul class=\"ref-list font-sm\"> <li id=\"qzae033-B1\"> <span class=\"label\"> [1]. </span> <cite> Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies <em> SOX2 </em> as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111\u20136. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ng.2405\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3557461/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/22941189/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Genet&amp;title=Comprehensive%20genomic%20analysis%20identifies%C2%A0SOX2%C2%A0as%20a%20frequently%20amplified%20gene%20in%20small-cell%20lung%20cancer&amp;volume=44&amp;publication_year=2012&amp;pages=1111-6&amp;pmid=22941189&amp;doi=10.1038/ng.2405&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B2\"> <span class=\"label\"> [2]. </span> <cite> George J, Lim JS, Jang SJ, Cun Y, Ozreti\u0107 L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47\u201353. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature14664\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4861069/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26168399/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Comprehensive%20genomic%20profiles%20of%20small%20cell%20lung%20cancer&amp;volume=524&amp;publication_year=2015&amp;pages=47-53&amp;pmid=26168399&amp;doi=10.1038/nature14664&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B3\"> <span class=\"label\"> [3]. </span> <cite> Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, et al. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol 2014;9:1324\u201331. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1097/JTO.0000000000000250\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4154841/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25122428/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=Therapeutic%20priority%20of%20the%20PI3K/AKT/mTOR%20pathway%20in%20small%20cell%20lung%20cancers%20as%20revealed%20by%20a%20comprehensive%20genomic%20analysis&amp;volume=9&amp;publication_year=2014&amp;pages=1324-31&amp;pmid=25122428&amp;doi=10.1097/JTO.0000000000000250&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B4\"> <span class=\"label\"> [4]. </span> <cite> Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 2019;19:289\u201397. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41568-019-0133-9\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6538259/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30926931/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Molecular%20subtypes%20of%20small%20cell%20lung%20cancer:%20a%20synthesis%20of%20human%20and%20mouse%20model%20data&amp;volume=19&amp;publication_year=2019&amp;pages=289-97&amp;pmid=30926931&amp;doi=10.1038/s41568-019-0133-9&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B5\"> <span class=\"label\"> [5]. </span> <cite> Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 2017;17:725\u201337. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nrc.2017.87\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29077690/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&amp;title=Small-cell%20lung%20cancer:%20what%20we%20know,%20what%20we%20need%20to%20know%20and%20the%20path%20forward&amp;volume=17&amp;publication_year=2017&amp;pages=725-37&amp;pmid=29077690&amp;doi=10.1038/nrc.2017.87&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B6\"> <span class=\"label\"> [6]. </span> <cite> Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol 2020;17:300\u201312. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41571-019-0316-z\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7212527/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32055013/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Clin%20Oncol&amp;title=Immunotherapeutic%20approaches%20for%20small-cell%20lung%20cancer&amp;volume=17&amp;publication_year=2020&amp;pages=300-12&amp;pmid=32055013&amp;doi=10.1038/s41571-019-0316-z&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B7\"> <span class=\"label\"> [7]. </span> <cite> Gazdar AF, Carney DN, Nau MM, Minna JD. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 1985;45:2924\u201330. </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/2985258/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Characterization%20of%20variant%20subclasses%20of%20cell%20lines%20derived%20from%20small%20cell%20lung%20cancer%20having%20distinctive%20biochemical,%20morphological,%20and%20growth%20properties&amp;volume=45&amp;publication_year=1985&amp;pages=2924-30&amp;pmid=2985258&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B8\"> <span class=\"label\"> [8]. </span> <cite> Graziano SL, Cowan BY, Carney DN, Bryke CR, Mitter NS, Johnson BE, et al. Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. Cancer Res 1987;47:2148\u201355. </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/3030544/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Small%20cell%20lung%20cancer%20cell%20line%20derived%20from%20a%20primary%20tumor%20with%20a%20characteristic%20deletion%20of%203p&amp;volume=47&amp;publication_year=1987&amp;pages=2148-55&amp;pmid=3030544&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B9\"> <span class=\"label\"> [9]. </span> <cite> Arvelo F, Poupon MF, Le Chevalier T. Establishment and characterization of five human small cell lung cancer cell lines from early tumor xenografts. Anticancer Res 1994;14:1893\u2013901. </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/7847823/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res&amp;title=Establishment%20and%20characterization%20of%20five%20human%20small%20cell%20lung%20cancer%20cell%20lines%20from%20early%20tumor%20xenografts&amp;volume=14&amp;publication_year=1994&amp;pages=1893-901&amp;pmid=7847823&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B10\"> <span class=\"label\"> [10]. </span> <cite> Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913\u201323. </cite> [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/2985257/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Establishment%20and%20identification%20of%20small%20cell%20lung%20cancer%20cell%20lines%20having%20classic%20and%20variant%20features&amp;volume=45&amp;publication_year=1985&amp;pages=2913-23&amp;pmid=2985257&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B11\"> <span class=\"label\"> [11]. </span> <cite> Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep 2016;16:1259\u201372. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.celrep.2016.06.081\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4972690/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27452466/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Rep&amp;title=ASCL1%20and%20NEUROD1%20reveal%20heterogeneity%20in%20pulmonary%20neuroendocrine%20tumors%20and%20regulate%20distinct%20genetic%20programs&amp;volume=16&amp;publication_year=2016&amp;pages=1259-72&amp;pmid=27452466&amp;doi=10.1016/j.celrep.2016.06.081&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B12\"> <span class=\"label\"> [12]. </span> <cite> Huang YH, Klingbeil O, He XY, Wu XS, Arun G, Lu B, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 2018;32:915\u201328. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1101/gad.314815.118\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6075037/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29945888/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genes%20Dev&amp;title=POU2F3%20is%20a%20master%20regulator%20of%20a%20tuft%20cell-like%20variant%20of%20small%20cell%20lung%20cancer&amp;volume=32&amp;publication_year=2018&amp;pages=915-28&amp;pmid=29945888&amp;doi=10.1101/gad.314815.118&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B13\"> <span class=\"label\"> [13]. </span> <cite> Baine MK, Hsieh MS, Lai WV, Egger JV, Jungbluth AA, Daneshbod Y, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol 2020;15:1823\u201335. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.jtho.2020.09.009\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8362797/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33011388/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&amp;title=SCLC%20subtypes%20defined%20by%20ASCL1,%20NEUROD1,%20POU2F3,%20and%20YAP1:%20a%20comprehensive%20immunohistochemical%20and%20histopathologic%20characterization&amp;volume=15&amp;publication_year=2020&amp;pages=1823-35&amp;pmid=33011388&amp;doi=10.1016/j.jtho.2020.09.009&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B14\"> <span class=\"label\"> [14]. </span> <cite> Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39:346\u201360.e7. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2020.12.014\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8143037/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33482121/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Patterns%20of%20transcription%20factor%20programs%20and%20immune%20pathway%20activation%20define%20four%20major%20subtypes%20of%20SCLC%20with%20distinct%20therapeutic%20vulnerabilities&amp;volume=39&amp;publication_year=2021&amp;pages=346-60.e7&amp;pmid=33482121&amp;doi=10.1016/j.ccell.2020.12.014&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B15\"> <span class=\"label\"> [15]. </span> <cite> Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394:1929\u201339. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/S0140-6736(19)32222-6\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31590988/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Durvalumab%20plus%20platinum%E2%80%93etoposide%20versus%20platinum%E2%80%93etoposide%20in%20first-line%20treatment%20of%20extensive-stage%20small-cell%20lung%20cancer%20(CASPIAN):%20a%20randomised,%20controlled,%20open-label,%20phase%203%20trial&amp;volume=394&amp;publication_year=2019&amp;pages=1929-39&amp;pmid=31590988&amp;doi=10.1016/S0140-6736(19)32222-6&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B16\"> <span class=\"label\"> [16]. </span> <cite> Chan JM, Quintanal-Villalonga \u00c1, Gao VR, Xie Y, Allaj V, Chaudhary O, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell 2021;39:1479\u201396.e18. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2021.09.008\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8628860/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34653364/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Signatures%20of%20plasticity,%20metastasis,%20and%20immunosuppression%20in%20an%20atlas%20of%20human%20small%20cell%20lung%20cancer&amp;volume=39&amp;publication_year=2021&amp;pages=1479-96.e18&amp;pmid=34653364&amp;doi=10.1016/j.ccell.2021.09.008&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B17\"> <span class=\"label\"> [17]. </span> <cite> Ni X, Tan Z, Ding C, Zhang C, Song L, Yang S, et al. A region-resolved mucosa proteome of the human stomach. Nat Commun 2019;10:39. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41467-018-07960-x\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6318339/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30604760/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=A%20region-resolved%20mucosa%20proteome%20of%20the%20human%20stomach&amp;volume=10&amp;publication_year=2019&amp;pages=39&amp;pmid=30604760&amp;doi=10.1038/s41467-018-07960-x&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B18\"> <span class=\"label\"> [18]. </span> <cite> Mun DG, Bhin J, Kim S, Kim H, Jung JH, Jung Y, et al. Proteogenomic characterization of human early-onset gastric cancer. Cancer Cell 2019;35:111\u201324.e10. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2018.12.003\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30645970/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Proteogenomic%20characterization%20of%20human%20early-onset%20gastric%20cancer&amp;volume=35&amp;publication_year=2019&amp;pages=111-24.e10&amp;pmid=30645970&amp;doi=10.1016/j.ccell.2018.12.003&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B19\"> <span class=\"label\"> [19]. </span> <cite> Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 2019;567:257\u201361. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41586-019-0987-8\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/30814741/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Proteomics%20identifies%20new%20therapeutic%20targets%20of%20early-stage%20hepatocellular%20carcinoma&amp;volume=567&amp;publication_year=2019&amp;pages=257-61&amp;pmid=30814741&amp;doi=10.1038/s41586-019-0987-8&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B20\"> <span class=\"label\"> [20]. </span> <cite> Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 2019;179:561\u201377.e22. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.cell.2019.08.052\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31585088/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Integrated%20proteogenomic%20characterization%20of%20HBV-related%20hepatocellular%20carcinoma&amp;volume=179&amp;publication_year=2019&amp;pages=561-77.e22&amp;pmid=31585088&amp;doi=10.1016/j.cell.2019.08.052&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B21\"> <span class=\"label\"> [21]. </span> <cite> Shrestha R, Llaurado Fernandez M, Dawson A, Hoenisch J, Volik S, Lin YY, et al. Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Cancer Res 2021;81:1681\u201394. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/0008-5472.CAN-20-2222\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33441310/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=Multiomics%20characterization%20of%20low-grade%20serous%20ovarian%20carcinoma%20identifies%20potential%20biomarkers%20of%20MEK%20inhibitor%20sensitivity%20and%20therapeutic%20vulnerability&amp;volume=81&amp;publication_year=2021&amp;pages=1681-94&amp;pmid=33441310&amp;doi=10.1158/0008-5472.CAN-20-2222&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B22\"> <span class=\"label\"> [22]. </span> <cite> Li C, Sun YD, Yu GY, Cui JR, Lou Z, Zhang H, et al. Integrated omics of metastatic colorectal cancer. Cancer Cell 2020;38:734\u201347.e9. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2020.08.002\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32888432/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Integrated%20omics%20of%20metastatic%20colorectal%20cancer&amp;volume=38&amp;publication_year=2020&amp;pages=734-47.e9&amp;pmid=32888432&amp;doi=10.1016/j.ccell.2020.08.002&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B23\"> <span class=\"label\"> [23]. </span> <cite> Zhan D, Zheng N, Zhao B, Cheng F, Tang Q, Liu X, et al. Expanding individualized therapeutic options via genoproteomics. Cancer Lett 2023;560:216123. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.canlet.2023.216123\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/36907503/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Lett&amp;title=Expanding%20individualized%20therapeutic%20options%20via%20genoproteomics&amp;volume=560&amp;publication_year=2023&amp;pages=216123&amp;pmid=36907503&amp;doi=10.1016/j.canlet.2023.216123&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B24\"> <span class=\"label\"> [24]. </span> <cite> Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell 2020;182:200\u201325.e35. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.cell.2020.06.013\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7373300/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32649874/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Proteogenomic%20characterization%20reveals%20therapeutic%20vulnerabilities%20in%20lung%20adenocarcinoma&amp;volume=182&amp;publication_year=2020&amp;pages=200-25.e35&amp;pmid=32649874&amp;doi=10.1016/j.cell.2020.06.013&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B25\"> <span class=\"label\"> [25]. </span> <cite> Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, et al. A proteomic landscape of diffuse-type gastric cancer. Nat Commun 2018;9:1012. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41467-018-03121-2\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5843664/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29520031/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=A%20proteomic%20landscape%20of%20diffuse-type%20gastric%20cancer&amp;volume=9&amp;publication_year=2018&amp;pages=1012&amp;pmid=29520031&amp;doi=10.1038/s41467-018-03121-2&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B26\"> <span class=\"label\"> [26]. </span> <cite> Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:1441\u201364. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.6004/jnccn.2021.0058\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC10203822/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34902832/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Compr%20Canc%20Netw&amp;title=Small%20cell%20lung%20cancer,%20version%202.2022,%20NCCN%20clinical%20practice%20guidelines%20in%20oncology&amp;volume=19&amp;publication_year=2021&amp;pages=1441-64&amp;pmid=34902832&amp;doi=10.6004/jnccn.2021.0058&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B27\"> <span class=\"label\"> [27]. </span> <cite> Fischbach H, D\u00f6ring M, Nikles D, Lehnert E, Baldauf C, Kalinke U, et al. Ultrasensitive quantification of TAP-dependent antigen compartmentalization in scarce primary immune cell subsets. Nat Commun 2015;6:6199. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ncomms7199\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4347055/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25656091/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Ultrasensitive%20quantification%20of%20TAP-dependent%20antigen%20compartmentalization%20in%20scarce%20primary%20immune%20cell%20subsets&amp;volume=6&amp;publication_year=2015&amp;pages=6199&amp;pmid=25656091&amp;doi=10.1038/ncomms7199&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B28\"> <span class=\"label\"> [28]. </span> <cite> Palomar G, Dudek K, Wielstra B, Jockusch EL, Vinkler M, Arntzen JW, et al. Molecular evolution of antigen-processing genes in salamanders: do they coevolve with MHC class I genes? Genome Biol Evol 2021;13:evaa259. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/gbe/evaa259\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7883663/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33501944/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Genome%20Biol%20Evol&amp;title=Molecular%20evolution%20of%20antigen-processing%20genes%20in%20salamanders:%20do%20they%20coevolve%20with%20MHC%20class%20I%20genes?&amp;volume=13&amp;publication_year=2021&amp;pages=evaa259&amp;pmid=33501944&amp;doi=10.1093/gbe/evaa259&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B29\"> <span class=\"label\"> [29]. </span> <cite> Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov 2017;7:1376\u201393. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/2159-8290.CD-17-0797\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5728441/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29146569/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=Found%20in%20translation:%20how%20preclinical%20research%20is%20guiding%20the%20clinical%20development%20of%20the%20BCL2-selective%20inhibitor%20venetoclax&amp;volume=7&amp;publication_year=2017&amp;pages=1376-93&amp;pmid=29146569&amp;doi=10.1158/2159-8290.CD-17-0797&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B30\"> <span class=\"label\"> [30]. </span> <cite> Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol 2020;13:104. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1186/s13045-020-00937-8\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7385862/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32723346/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Hematol%20Oncol&amp;title=EZH2:%20a%20novel%20target%20for%20cancer%20treatment&amp;volume=13&amp;publication_year=2020&amp;pages=104&amp;pmid=32723346&amp;doi=10.1186/s13045-020-00937-8&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B31\"> <span class=\"label\"> [31]. </span> <cite> Petersen SL, Chen TT, Lawrence DA, Marsters SA, Gonzalvez F, Ashkenazi A. TRAF2 is a biologically important necroptosis suppressor. Cell Death Differ 2015;22:1846\u201357. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/cdd.2015.35\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4648330/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/25882049/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Death%20Differ&amp;title=TRAF2%20is%20a%20biologically%20important%20necroptosis%20suppressor&amp;volume=22&amp;publication_year=2015&amp;pages=1846-57&amp;pmid=25882049&amp;doi=10.1038/cdd.2015.35&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B32\"> <span class=\"label\"> [32]. </span> <cite> Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line serplulimab <em> vs </em> placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA 2022;328:1223\u201332. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1001/jama.2022.16464\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC9516323/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/36166026/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Effect%20of%20first-line%20serplulimab%20vs%20placebo%20added%20to%20chemotherapy%20on%20survival%20in%20patients%20with%20extensive-stage%20small%20cell%20lung%20cancer:%20the%20ASTRUM-005%20randomized%20clinical%20trial&amp;volume=328&amp;publication_year=2022&amp;pages=1223-32&amp;pmid=36166026&amp;doi=10.1001/jama.2022.16464&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B33\"> <span class=\"label\"> [33]. </span> <cite> El Sayed R, Blais N. Immunotherapy in extensive-stage small cell lung cancer. Curr Oncol 2021;28:4093\u2013108. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/curroncol28050347\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC8534845/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34677265/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Curr%20Oncol&amp;title=Immunotherapy%20in%20extensive-stage%20small%20cell%20lung%20cancer&amp;volume=28&amp;publication_year=2021&amp;pages=4093-108&amp;pmid=34677265&amp;doi=10.3390/curroncol28050347&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B34\"> <span class=\"label\"> [34]. </span> <cite> Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2\u2013SLFN11 axis. Cancer Cell 2017;31:286\u201399. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ccell.2017.01.006\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5313262/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28196596/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Chemosensitive%20relapse%20in%20small%20cell%20lung%20cancer%20proceeds%20through%20an%20EZH2%E2%80%93SLFN11%20axis&amp;volume=31&amp;publication_year=2017&amp;pages=286-99&amp;pmid=28196596&amp;doi=10.1016/j.ccell.2017.01.006&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B35\"> <span class=\"label\"> [35]. </span> <cite> Leslie M. First EZH2 inhibitor approved-for rare sarcoma. Cancer Discov 2020;10:333\u20134. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/2159-8290.CD-NB2020-006\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32041739/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Discov&amp;title=First%20EZH2%20inhibitor%20approved-for%20rare%20sarcoma&amp;volume=10&amp;publication_year=2020&amp;pages=333-4&amp;pmid=32041739&amp;doi=10.1158/2159-8290.CD-NB2020-006&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B36\"> <span class=\"label\"> [36]. </span> <cite> Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin Cancer Res 2020;26:290\u2013300. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1078-0432.CCR-19-1351\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6942613/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31562203/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Targeting%20EZH2%20enhances%20antigen%20presentation,%20antitumor%20immunity,%20and%20circumvents%20anti-PD-1%20resistance%20in%20head%20and%20neck%20cancer&amp;volume=26&amp;publication_year=2020&amp;pages=290-300&amp;pmid=31562203&amp;doi=10.1158/1078-0432.CCR-19-1351&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B37\"> <span class=\"label\"> [37]. </span> <cite> Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006;52:93\u20137. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.lungcan.2005.12.002\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/16488055/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=Gefitinib%20in%20patients%20with%20chemo-sensitive%20and%20chemo-refractory%20relapsed%20small%20cell%20cancers:%20a%20Hoosier%20Oncology%20Group%20phase%20II%20trial&amp;volume=52&amp;publication_year=2006&amp;pages=93-7&amp;pmid=16488055&amp;doi=10.1016/j.lungcan.2005.12.002&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B38\"> <span class=\"label\"> [38]. </span> <cite> Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017;28:1713\u201329. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/annonc/mdx175\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6246616/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28407110/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Prognostic%20and%20predictive%20value%20of%20primary%20tumour%20side%20in%20patients%20with%20RAS%20wild-type%20metastatic%20colorectal%20cancer%20treated%20with%20chemotherapy%20and%20EGFR%20directed%20antibodies%20in%20six%20randomized%20trials&amp;volume=28&amp;publication_year=2017&amp;pages=1713-29&amp;pmid=28407110&amp;doi=10.1093/annonc/mdx175&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B39\"> <span class=\"label\"> [39]. </span> <cite> Mak DWS, Li S, Minchom A. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer. Eur J Cancer 2019;119:132\u201350. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.ejca.2019.04.037\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/31445197/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&amp;title=Challenging%20the%20recalcitrant%20disease-developing%20molecularly%20driven%20treatments%20for%20small%20cell%20lung%20cancer&amp;volume=119&amp;publication_year=2019&amp;pages=132-50&amp;pmid=31445197&amp;doi=10.1016/j.ejca.2019.04.037&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B40\"> <span class=\"label\"> [40]. </span> <cite> Held L, Siu C, Shadman M. Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far. Expert Opin Pharmacother 2021;22:655\u201365. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1080/14656566.2021.1882421\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33645381/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Pharmacother&amp;title=Venetoclax%20as%20a%20therapeutic%20option%20for%20the%20treatment%20of%20chronic%20lymphocytic%20leukemia:%20the%20evidence%20so%20far&amp;volume=22&amp;publication_year=2021&amp;pages=655-65&amp;pmid=33645381&amp;doi=10.1080/14656566.2021.1882421&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B41\"> <span class=\"label\"> [41]. </span> <cite> Lochmann TL, Floros KV, Naseri M, Powell KM, Cook W, March RJ, et al. Venetoclax is effective in small-cell lung cancers with high BCL-2 expression. Clin Cancer Res 2018;24:360\u20139. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/1078-0432.CCR-17-1606\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5771805/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29118061/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&amp;title=Venetoclax%20is%20effective%20in%20small-cell%20lung%20cancers%20with%20high%20BCL-2%20expression&amp;volume=24&amp;publication_year=2018&amp;pages=360-9&amp;pmid=29118061&amp;doi=10.1158/1078-0432.CCR-17-1606&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B42\"> <span class=\"label\"> [42]. </span> <cite> Liewer S, Huddleston A. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. Expert Opin Investig Drugs 2018;27:105\u201312. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1080/13543784.2018.1417382\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29260599/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Investig%20Drugs&amp;title=Alisertib:%20a%20review%20of%20pharmacokinetics,%20efficacy%20and%20toxicity%20in%20patients%20with%20hematologic%20malignancies%20and%20solid%20tumors&amp;volume=27&amp;publication_year=2018&amp;pages=105-12&amp;pmid=29260599&amp;doi=10.1080/13543784.2018.1417382&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B43\"> <span class=\"label\"> [43]. </span> <cite> V\u00e9n\u00e9reau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol. 2015;6:422. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3389/fimmu.2015.00422\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4539554/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26347745/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Front%20Immunol&amp;title=DAMPs%20from%20cell%20death%20to%20new%20life&amp;volume=6&amp;publication_year=2015&amp;pages=422&amp;pmid=26347745&amp;doi=10.3389/fimmu.2015.00422&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B44\"> <span class=\"label\"> [44]. </span> <cite> Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S, et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells 2020;9:1823. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.3390/cells9081823\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC7464343/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/32752206/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cells&amp;title=Necroptosis%20in%20immuno-oncology%20and%20cancer%20immunotherapy&amp;volume=9&amp;publication_year=2020&amp;pages=1823&amp;pmid=32752206&amp;doi=10.3390/cells9081823&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B45\"> <span class=\"label\"> [45]. </span> <cite> Bist P, Leow SC, Phua QH, Shu S, Zhuang Q, Loh WT, et al. Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-\u03baB: implication in breast cancer metastasis. Oncogene 2011;30:3174\u201385. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/onc.2011.28\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/21383699/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Annexin-1%20interacts%20with%20NEMO%20and%20RIP1%20to%20constitutively%20activate%20IKK%20complex%20and%20NF-%CE%BAB:%20implication%20in%20breast%20cancer%20metastasis&amp;volume=30&amp;publication_year=2011&amp;pages=3174-85&amp;pmid=21383699&amp;doi=10.1038/onc.2011.28&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B46\"> <span class=\"label\"> [46]. </span> <cite> Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, et al. The receptor interacting protein 1 inhibits p53 induction through NF-\u03baB activation and confers a worse prognosis in glioblastoma. Cancer Res 2009;69:2809\u201316. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1158/0008-5472.CAN-08-4079\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2859885/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/19339267/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&amp;title=The%20receptor%20interacting%20protein%201%20inhibits%20p53%20induction%20through%20NF-%CE%BAB%20activation%20and%20confers%20a%20worse%20prognosis%20in%20glioblastoma&amp;volume=69&amp;publication_year=2009&amp;pages=2809-16&amp;pmid=19339267&amp;doi=10.1158/0008-5472.CAN-08-4079&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B47\"> <span class=\"label\"> [47]. </span> <cite> McCormick KD, Ghosh A, Trivedi S, Wang L, Coyne CB, Ferris RL, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. Carcinogenesis 2016;37:522\u20139. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/carcin/bgw032\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6086476/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26992898/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Carcinogenesis&amp;title=Innate%20immune%20signaling%20through%20differential%20RIPK1%20expression%20promote%20tumor%20progression%20in%20head%20and%20neck%20squamous%20cell%20carcinoma&amp;volume=37&amp;publication_year=2016&amp;pages=522-9&amp;pmid=26992898&amp;doi=10.1093/carcin/bgw032&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B48\"> <span class=\"label\"> [48]. </span> <cite> Li X, Guo J, Ding AP, Qi WW, Zhang PH, Lv J, et al. Association of mixed lineage kinase domain-like protein expression with prognosis in patients with colon cancer. Technol Cancer Res Treat 2017;16:428\u201334. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1177/1533034616655909\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5616063/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27432118/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Technol%20Cancer%20Res%20Treat&amp;title=Association%20of%20mixed%20lineage%20kinase%20domain-like%20protein%20expression%20with%20prognosis%20in%20patients%20with%20colon%20cancer&amp;volume=16&amp;publication_year=2017&amp;pages=428-34&amp;pmid=27432118&amp;doi=10.1177/1533034616655909&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B49\"> <span class=\"label\"> [49]. </span> <cite> Li L, Yu S, Zang C. Low necroptosis process predicts poor treatment outcome of human papillomavirus positive cervical cancers by decreasing tumor-associated macrophages M1 polarization. Gynecol Obstet Invest 2018;83:259\u201367. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1159/000487434\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29621771/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Gynecol%20Obstet%20Invest&amp;title=Low%20necroptosis%20process%20predicts%20poor%20treatment%20outcome%20of%20human%20papillomavirus%20positive%20cervical%20cancers%20by%20decreasing%20tumor-associated%20macrophages%20M1%20polarization&amp;volume=83&amp;publication_year=2018&amp;pages=259-67&amp;pmid=29621771&amp;doi=10.1159/000487434&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B50\"> <span class=\"label\"> [50]. </span> <cite> He L, Peng K, Liu Y, Xiong J, Zhu FF. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. Onco Targets Ther 2013;6:1539\u201343. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.2147/OTT.S52805\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC3817086/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/24204164/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Onco%20Targets%20Ther&amp;title=Low%20expression%20of%20mixed%20lineage%20kinase%20domain-like%20protein%20is%20associated%20with%20poor%20prognosis%20in%20ovarian%20cancer%20patients&amp;volume=6&amp;publication_year=2013&amp;pages=1539-43&amp;pmid=24204164&amp;doi=10.2147/OTT.S52805&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B51\"> <span class=\"label\"> [51]. </span> <cite> Colbert LE, Fisher SB, Hardy CW, Hall WA, Saka B, Shelton JW, et al. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Cancer 2013;119:3148\u201355. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1002/cncr.28144\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4389890/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23720157/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Pronecrotic%20mixed%20lineage%20kinase%20domain-like%20protein%20expression%20is%20a%20prognostic%20biomarker%20in%20patients%20with%20early-stage%20resected%20pancreatic%20adenocarcinoma&amp;volume=119&amp;publication_year=2013&amp;pages=3148-55&amp;pmid=23720157&amp;doi=10.1002/cncr.28144&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B52\"> <span class=\"label\"> [52]. </span> <cite> Jiao D, Cai Z, Choksi S, Ma D, Choe M, Kwon HJ, et al. Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis. Cell Res 2018;28:868\u201370. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/s41422-018-0058-y\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC6082890/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/29941926/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Cell%20Res&amp;title=Necroptosis%20of%20tumor%20cells%20leads%20to%20tumor%20necrosis%20and%20promotes%20tumor%20metastasis&amp;volume=28&amp;publication_year=2018&amp;pages=868-70&amp;pmid=29941926&amp;doi=10.1038/s41422-018-0058-y&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B53\"> <span class=\"label\"> [53]. </span> <cite> Ruan J, Mei L, Zhu Q, Shi G, Wang H. Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer. Int J Clin Exp Pathol 2015;8:15035\u20138. </cite> [ <a class=\"usa-link\" href=\"/articles/PMC4713627/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26823841/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Int%20J%20Clin%20Exp%20Pathol&amp;title=Mixed%20lineage%20kinase%20domain-like%20protein%20is%20a%20prognostic%20biomarker%20for%20cervical%20squamous%20cell%20cancer&amp;volume=8&amp;publication_year=2015&amp;pages=15035-8&amp;pmid=26823841&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B54\"> <span class=\"label\"> [54]. </span> <cite> Zhai E, Chen J, Wang K, Ye Z, Wu H, Chen C, et al. Prognostic value of mixed lineage kinase domain-like protein expression in the survival of patients with gastric caner. Tumour Biol 2016;37:13679\u201385. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1007/s13277-016-5229-1\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27473085/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Tumour%20Biol&amp;title=Prognostic%20value%20of%20mixed%20lineage%20kinase%20domain-like%20protein%20expression%20in%20the%20survival%20of%20patients%20with%20gastric%20caner&amp;volume=37&amp;publication_year=2016&amp;pages=13679-85&amp;pmid=27473085&amp;doi=10.1007/s13277-016-5229-1&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B55\"> <span class=\"label\"> [55]. </span> <cite> Yang C, Sengupta S, Hegde PM, Mitra J, Jiang S, Holey B, et al. Regulation of oxidized base damage repair by chromatin assembly factor 1 subunit A. Nucleic Acids Res 2017;45:739\u201348. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1093/nar/gkw1024\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC5314755/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/27794043/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&amp;title=Regulation%20of%20oxidized%20base%20damage%20repair%20by%20chromatin%20assembly%20factor%201%20subunit%20A&amp;volume=45&amp;publication_year=2017&amp;pages=739-48&amp;pmid=27794043&amp;doi=10.1093/nar/gkw1024&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B56\"> <span class=\"label\"> [56]. </span> <cite> Nera B, Huang HS, Lai T, Xu L. Elevated levels of TRF2 induce telomeric ultrafine anaphase bridges and rapid telomere deletions. Nat Commun 2015;6:10132. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/ncomms10132\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4686832/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/26640040/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Commun&amp;title=Elevated%20levels%20of%20TRF2%20induce%20telomeric%20ultrafine%20anaphase%20bridges%20and%20rapid%20telomere%20deletions&amp;volume=6&amp;publication_year=2015&amp;pages=10132&amp;pmid=26640040&amp;doi=10.1038/ncomms10132&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B57\"> <span class=\"label\"> [57]. </span> <cite> Lee JH, You J, Dobrota E, Skalnik DG. Identification and characterization of a novel human PP1 phosphatase complex. J Biol Chem 2010;285:24466\u201376. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1074/jbc.M110.109801\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC2915683/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20516061/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=J%20Biol%20Chem&amp;title=Identification%20and%20characterization%20of%20a%20novel%20human%20PP1%20phosphatase%20complex&amp;volume=285&amp;publication_year=2010&amp;pages=24466-76&amp;pmid=20516061&amp;doi=10.1074/jbc.M110.109801&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B58\"> <span class=\"label\"> [58]. </span> <cite> Nayak A, Dutta M, Roychowdhury A. Emerging oncogene ATAD2: signaling cascades and therapeutic initiatives. Life Sci 2021;276:119322. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1016/j.lfs.2021.119322\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/33711386/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Life%20Sci&amp;title=Emerging%20oncogene%20ATAD2:%20signaling%20cascades%20and%20therapeutic%20initiatives&amp;volume=276&amp;publication_year=2021&amp;pages=119322&amp;pmid=33711386&amp;doi=10.1016/j.lfs.2021.119322&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B59\"> <span class=\"label\"> [59]. </span> <cite> Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013;494:492\u20136. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nature11935\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC4636055/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/23446422/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Replication%20stress%20links%20structural%20and%20numerical%20cancer%20chromosomal%20instability&amp;volume=494&amp;publication_year=2013&amp;pages=492-6&amp;pmid=23446422&amp;doi=10.1038/nature11935&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B60\"> <span class=\"label\"> [60]. </span> <cite> Feng W, Yonezawa M, Ye J, Jenuwein T, Grummt I. PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation. Nat Struct Mol Biol 2010;17:445\u201350. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nsmb.1778\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/20208542/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Struct%20Mol%20Biol&amp;title=PHF8%20activates%20transcription%20of%20rRNA%20genes%20through%20H3K4me3%20binding%20and%20H3K9me1/2%20demethylation&amp;volume=17&amp;publication_year=2010&amp;pages=445-50&amp;pmid=20208542&amp;doi=10.1038/nsmb.1778&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B61\"> <span class=\"label\"> [61]. </span> <cite> Lee YC, Kim YJ. Requirement for a functional interaction between mediator components Med6 and Srb4 in RNA polymerase II transcription. Mol Cell Biol 1998;18:5364\u201370. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1128/mcb.18.9.5364\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"/articles/PMC109121/\"> PMC free article </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/9710620/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Mol%20Cell%20Biol&amp;title=Requirement%20for%20a%20functional%20interaction%20between%20mediator%20components%20Med6%20and%20Srb4%20in%20RNA%20polymerase%20II%20transcription&amp;volume=18&amp;publication_year=1998&amp;pages=5364-70&amp;pmid=9710620&amp;doi=10.1128/mcb.18.9.5364&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B62\"> <span class=\"label\"> [62]. </span> <cite> Feng J, Ding C, Qiu N, Ni X, Zhan D, Liu W, et al. Firmiana: towards a one-stop proteomic cloud platform for data processing and analysis. Nat Biotechnol 2017;35:409\u201312. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1038/nbt.3825\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/28486446/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Nat%20Biotechnol&amp;title=Firmiana:%20towards%20a%20one-stop%20proteomic%20cloud%20platform%20for%20data%20processing%20and%20analysis&amp;volume=35&amp;publication_year=2017&amp;pages=409-12&amp;pmid=28486446&amp;doi=10.1038/nbt.3825&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> <li id=\"qzae033-B63\"> <span class=\"label\"> [63]. </span> <cite> Huang W, Zhan D, Li Y, Zheng N, Wei X, Bai B, et al. Proteomics provides individualized options of precision medicine for patients with gastric cancer. Sci China Life Sci 2021;64:1199\u2013211. </cite> [ <a class=\"usa-link usa-link--external\" href=\"https://doi.org/10.1007/s11427-021-1966-4\" rel=\"noopener noreferrer\" target=\"_blank\"> DOI </a> ] [ <a class=\"usa-link\" href=\"https://pubmed.ncbi.nlm.nih.gov/34258712/\"> PubMed </a> ] [ <a class=\"usa-link usa-link--external\" href=\"https://scholar.google.com/scholar_lookup?journal=Sci%20China%20Life%20Sci&amp;title=Proteomics%20provides%20individualized%20options%20of%20precision%20medicine%20for%20patients%20with%20gastric%20cancer&amp;volume=64&amp;publication_year=2021&amp;pages=1199-211&amp;pmid=34258712&amp;doi=10.1007/s11427-021-1966-4&amp;\" rel=\"noopener noreferrer\" target=\"_blank\"> Google Scholar </a> ] </li> </ul> </section> </section> <section class=\"associated-data\" id=\"_ad93_\" lang=\"en\"> <h2 class=\"pmc_sec_title\"> <a class=\"usa-anchor\" id=\"_ad93_-anchor\"> </a> Associated Data </h2> <p class=\"font-secondary\"> <em> This section collects any data citations, data availability statements, or supplementary materials included in this article. </em> </p> <section class=\"supplementary-materials\" id=\"_adsm93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Supplementary Materials </h3> <section class=\"sm xbox font-sm\" id=\"db_ds_supplementary-material1_reqid_\"> <div class=\"caption p\"> <span> qzae033_Supplementary_Data </span> </div> <div class=\"media p\"> <div class=\"caption\"> <a class=\"usa-link\" href=\"/articles/instance/11423856/bin/qzae033_supplementary_data.zip\"> qzae033_supplementary_data.zip </a> <sup> (37.5MB, zip) </sup> </div> </div> </section> </section> <section class=\"data-availability-statement\" id=\"_adda93_\" lang=\"en\"> <h3 class=\"pmc_sec_title\"> Data Availability Statement </h3> <p> All data and search results have been deposited to the iProX database (iProX: IPX0004230000), which are publicly accessible at <a class=\"usa-link usa-link--external\" href=\"http://www.iprox.org\" rel=\"noopener noreferrer\" target=\"_blank\"> http://www.iprox.org </a> . </p> </section> </section> </section> <footer class=\"p courtesy-note font-secondary font-sm text-center\"> <hr class=\"headless\"/> <p> Articles from Genomics, Proteomics &amp; Bioinformatics are provided here courtesy of <strong> Oxford University Press </strong> </p> </footer> </section> </article> </main> </div> </div> </div> <div class=\"pmc-sidenav desktop:grid-col-4 display-flex\"> <section aria-label=\"Article resources and navigation\" class=\"pmc-sidenav__container\"> <button class=\"usa-button pmc-sidenav__container__close usa-button--unstyled\" type=\"button\"> <img alt=\"Close\" role=\"img\" src=\"/static/img/usa-icons/close.svg\"/> </button> <div class=\"display-none desktop:display-block\"> <section class=\"margin-top-4 desktop:margin-top-0\"> <h2 class=\"margin-top-0\"> ACTIONS </h2> <ul class=\"usa-list usa-list--unstyled usa-list--actions\"> <li> <a class=\"usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"https://doi.org/10.1093/gpbjnl/qzae033\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#launch\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 padding-right-2\"> View on publisher site </span> </a> </li> <li> <a class=\"usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1\" href=\"pdf/qzae033.pdf\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> PDF (4.6 MB) </span> </a> </li> <li> <button aria-label=\"Open dialog with citation text in different styles\" class=\"usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1\" role=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#format_quote\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Cite </span> </button> </li> <li> <button aria-label=\"Save article in MyNCBI collections.\" class=\"usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-full\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-full.svg#icon\"> </use> </svg> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3 usa-icon--bookmark-empty\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/action-bookmark-empty.svg#icon\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1\"> Collections </span> </button> </li> <li class=\"pmc-permalink\"> <button aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Show article permalink\" class=\"usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" hidden=\"\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#share\"> </use> </svg> <span class=\"display-inline-flex flex-justify-center flex-1 button-label\"> Permalink </span> </button> <div class=\"pmc-permalink__dropdown\" hidden=\"\"> <div class=\"pmc-permalink__dropdown__container\"> <h2 class=\"usa-modal__heading margin-top-0 margin-bottom-2\"> PERMALINK </h2> <div class=\"pmc-permalink__dropdown__content\"> <input aria-label=\"Article permalink\" class=\"usa-input\" type=\"text\" value=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC11423856/\"/> <button aria-expanded=\"false\" class=\"usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0\" title=\"Copy article permalink\"> <svg aria-hidden=\"true\" class=\"usa-icon\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span class=\"margin-left-1\"> Copy </span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class=\"pmc-resources margin-top-6 desktop:margin-top-4\"> <h2 class=\"margin-top-0\"> RESOURCES </h2> <div class=\"usa-accordion usa-accordion--multiselectable\"> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-similar-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Similar articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-similar-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-cited-by-other-articles\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Cited by other articles </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-cited-by-other-articles\"> </div> <h3 class=\"usa-accordion__heading\"> <button aria-controls=\"resources-links-to-ncbi-databases\" aria-expanded=\"false\" class=\"usa-accordion__button\" type=\"button\"> Links to NCBI Databases </button> </h3> <div class=\"usa-accordion__content usa-prose\" hidden=\"\" id=\"resources-links-to-ncbi-databases\"> </div> </div> </section> <section class=\"usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4\"> <nav aria-label=\"On this page\" class=\"usa-in-page-nav__nav\"> <h2 class=\"usa-in-page-nav__heading\" tabindex=\"0\"> On this page </h2> <ul class=\"usa-in-page-nav__list\"> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#abstract1\"> Abstract </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec1\"> Introduction </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec2\"> Results </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec9\"> Discussion </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec10\"> Materials and methods </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec18\"> Ethical statement </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec19\"> Supplementary Material </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ack1\"> Acknowledgments </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#_ci93_\"> Contributor Information </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec20\"> Data availability </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec21\"> CRediT author statement </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec22\"> Supplementary material </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec23\"> Competing interests </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#sec24\"> ORCID </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#ref1\"> References </a> </li> <li class=\"usa-in-page-nav__item\"> <a class=\"usa-in-page-nav__link\" href=\"#_ad93_\"> Associated Data </a> </li> </ul> </nav> </section> </section> </div> <div aria-label=\"Citation Dialog\" class=\"overlay citation-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog citation-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Cite </h2> <button class=\"usa-button usa-button--unstyled close-overlay text-black width-auto\" tabindex=\"1\" type=\"button\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#close\"> </use> </svg> </button> </div> <div class=\"citation-text-block\"> <div class=\"citation-text margin-bottom-2\"> </div> <ul class=\"usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center\"> <li> <button class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus\" tabindex=\"2\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#content_copy\"> </use> </svg> <span> Copy </span> </button> </li> <li> <a class=\"usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button\" href=\"#\" role=\"button\" tabindex=\"3\" title=\"Download a file for external citation management software\"> <svg aria-hidden=\"true\" class=\"usa-icon width-3 height-3\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#file_download\"> </use> </svg> <span class=\"display-none mobile-lg:display-inline\"> Download .nbib </span> <span class=\"display-inline mobile-lg:display-none\"> .nbib </span> </a> </li> <li> <div class=\"display-inline-flex flex-align-center\"> <label class=\"usa-label margin-top-0\"> Format: </label> <select aria-label=\"Format\" class=\"usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4\" tabindex=\"4\"> <option value=\"AMA\"> AMA </option> <option value=\"APA\"> APA </option> <option value=\"MLA\"> MLA </option> <option selected=\"selected\" value=\"NLM\"> NLM </option> </select> </div> </li> </ul> <div class=\"dots-loading-indicator citation-loading-indicator\"> <div class=\"dot dot-1\"> </div> <div class=\"dot dot-2\"> </div> <div class=\"dot dot-3\"> </div> </div> </div> </div> </div> <div class=\"overlay collections-dialog-overlay\" role=\"dialog\"> <div aria-hidden=\"true\" class=\"dialog collections-dialog\" id=\"collections-action-dialog\" role=\"document\"> <div class=\"display-inline-flex flex-align-center flex-justify width-full margin-bottom-2\"> <h2 class=\"usa-modal__heading margin-0\"> Add to Collections </h2> </div> <div class=\"collections-action-panel action-panel\"> <form class=\"usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors\" id=\"collections-action-dialog-form\"> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"usa-radio\"> <input class=\"usa-radio__input usa-radio__input--tile collections-new margin-top-0\" id=\"collections-action-dialog-new\" name=\"collections\" type=\"radio\" value=\"new\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-new\"> Create a new collection </label> </div> <div class=\"usa-radio\"> <input checked=\"true\" class=\"usa-radio__input usa-radio__input--tile collections-existing\" id=\"collections-action-dialog-existing\" name=\"collections\" type=\"radio\" value=\"existing\"/> <label class=\"usa-radio__label\" for=\"collections-action-dialog-existing\"> Add to an existing collection </label> </div> </fieldset> <fieldset class=\"usa-fieldset margin-bottom-2\"> <div class=\"action-panel-control-wrap new-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-new\"> Name your collection <abbr class=\"usa-hint usa-hint--required text-no-underline\" title=\"required\"> * </abbr> </label> <input class=\"usa-input collections-action-add-to-new\" id=\"collections-action-dialog-add-to-new\" maxlength=\"\" name=\"add-to-new-collection\" pattern='[^\"&amp;=&lt;&gt;/]*' required=\"\" title='The following characters are not allowed in the Name field: \"&amp;=&lt;&gt;/' type=\"text\"/> </div> <div class=\"action-panel-control-wrap existing-collections-controls\"> <label class=\"usa-label margin-top-0\" for=\"collections-action-dialog-add-to-existing\"> Choose a collection </label> <select class=\"usa-select collections-action-add-to-existing\" id=\"collections-action-dialog-add-to-existing\"> </select> <div class=\"collections-retry-load-on-error usa-input-error-message selection-validation-message\"> Unable to load your collection due to an error <br/> <a href=\"#\"> Please try again </a> </div> </div> </fieldset> <div class=\"display-inline-flex\"> <button class=\"usa-button margin-top-0 action-panel-submit\" type=\"submit\"> Add </button> <button aria-label=\"Close 'Add to Collections' panel\" class=\"usa-button usa-button--outline margin-top-0 action-panel-cancel\" ref=\"linksrc=close_collections_panel\"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class=\"ncbi-footer ncbi-dark-background\"> <div class=\"ncbi-footer__icon-section\"> <div class=\"ncbi-footer__social-header\"> Follow NCBI </div> <div class=\"grid-container ncbi-footer__ncbi-social-icons-container\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://twitter.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"40\" viewbox=\"0 0 40 40\" width=\"40\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.facebook.com/ncbi.nlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"29\" viewbox=\"0 0 16 29\" width=\"16\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://www.linkedin.com/company/ncbinlm\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"23\" viewbox=\"0 0 26 24\" width=\"25\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z\"> </path> <path d=\"M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z\"> </path> <path d=\"M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on LinkedIn </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://github.com/ncbi\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"27\" viewbox=\"0 0 28 28\" width=\"28\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI on GitHub </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--gray\" href=\"https://ncbiinsights.ncbi.nlm.nih.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"26\" viewbox=\"0 0 27 27\" width=\"26\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z\"> </path> <path d=\"M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z\"> </path> <path d=\"M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z\"> </path> </svg> <span class=\"usa-sr-only\"> NCBI RSS feed </span> </a> </div> </div> <div class=\"grid-container ncbi-footer__container\"> <div class=\"grid-row ncbi-footer__main-content-container\"> <div class=\"ncbi-footer__column\"> <p class=\"ncbi-footer__circled-icons-heading\"> Connect with NLM </p> <div class=\"ncbi-footer__circled-icons-list\"> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://twitter.com/nlm_nih\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"32\" viewbox=\"0 0 40 40\" width=\"32\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on X (formerly known as Twitter) </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.facebook.com/nationallibraryofmedicine\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"24\" viewbox=\"0 0 13 24\" width=\"13\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on Facebook </span> </a> <a class=\"ncbi-footer__social-icon ncbi-footer__social-icon--circled\" href=\"https://www.youtube.com/user/NLMNIH\" rel=\"noreferrer noopener\" target=\"_blank\"> <svg aria-hidden=\"true\" fill=\"none\" focusable=\"false\" height=\"15\" viewbox=\"0 0 21 15\" width=\"21\" xmlns=\"http://www.w3.org/2000/svg\"> <path d=\"M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z\" fill=\"white\"> </path> </svg> <span class=\"usa-sr-only\"> NLM on YouTube </span> </a> </div> </div> <address class=\"ncbi-footer__address ncbi-footer__column\"> <p> <a class=\"usa-link usa-link--external\" href=\"https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323\" rel=\"noopener noreferrer\" target=\"_blank\"> National Library of Medicine <br/> 8600 Rockville Pike <br/> Bethesda, MD 20894 </a> </p> </address> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/web_policies.html\"> Web Policies </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office\"> FOIA </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/vulnerability-disclosure-policy/index.html\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS Vulnerability Disclosure </a> </li> </ul> <ul class=\"usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column\"> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal\"> Help </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/accessibility.html\"> Accessibility </a> </li> <li class=\"ncbi-footer__vertical-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/careers/careers.html\"> Careers </a> </li> </ul> </div> <div class=\"grid-row grid-col-12\"> <ul class=\"ncbi-footer__bottom-links-list\"> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nlm.nih.gov/\"> NLM </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--alt ncbi-footer__link\" href=\"https://www.nih.gov/\"> NIH </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.hhs.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> HHS </a> </li> <li class=\"ncbi-footer__bottom-list-item\"> <a class=\"usa-link usa-link--external usa-link--alt ncbi-footer__link\" href=\"https://www.usa.gov/\" rel=\"noreferrer noopener\" target=\"_blank\"> USA.gov </a> </li> </ul> </div> </div> </footer> <div id=\"ZN_dikYWqsjiUWN0Q5\"> </div> <button class=\"back-to-top\"> <label> Back to Top </label> <svg aria-hidden=\"true\" class=\"usa-icon order-0\" focusable=\"false\" role=\"img\"> <use xlink:href=\"/static/img/sprite.svg#arrow_upward\"> </use> </svg> </button> <div class=\"fake-body-scroll\"> </div> <div class=\"fake-body-scroll\"> </div> <div class=\"QSIFeedbackButton\"> <button aria-label=\"Tell us what you think!\" id=\"QSIFeedbackButton-btn\" role=\"button\"> <img alt=\"Tell us what you think!\" src=\"https://iad1.qualtrics.com/WRQualtricsSiteIntercept/Graphic.php?IM=IM_3xWqwNkIHc7cA0S\"/> </button> </div> </body> </html>) and a list of known data repositories (bigd.big.ac.cn, massive.ucsd.edu, www.ebi.ac.uk, www.iprox.cn, proteomecentral.proteomexchange.org, www.proteomexchange.org, pdc.cancer.gov, doi.org, www.ncbi.nlm.nih.gov). Given this information, please return a JSON array of objects where each object has the following structure:\n- `dataset_identifier`: The dataset identifier (a code). If not found, set it to \"n/a\".\n- `repository_reference`: The URL or reference to the data repository. If not found, set it to \"n/a\".\n\nPlease follow these strict instructions:\n- The output must be a valid JSON array of objects.\n- Each object must contain the keys `dataset_identifier` and `repository_reference`.\n- Any other output format will be considered invalid."}]}]